QUARTERLY REPORT

Q3 2021 — Form 10-Q

Q3 2021PDF · 59 pages585 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR
☐☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey 	22-1918501
(State or other jurisdiction of incorporation) 	(I.R.S. Employer Identification No.)
2000 Galloping Hill Road
Kenilworth 	New Jersey 	07033
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) 	(908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock ($0.50 par value) 	MRK 	New York Stock Exchange
0.500% Notes due 2024 	MRK 24 	New York Stock Exchange
1.875% Notes due 2026 	MRK/26 	New York Stock Exchange
2.500% Notes due 2034 	MRK/34 	New York Stock Exchange
1.375% Notes due 2036 	MRK 36A 	New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes 	☒	☒ 	No 	☐	☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 	☒	☒ 	No 	☐	☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer 	☒	☒ 	Accelerated filer 	☐	☐
Non-accelerated filer 	☐	☐ 	Smaller reporting company 	☐	☐
Emerging growth company 	☐	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. 	☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes 	☐ 	No 	☒	☒
The number of shares of common stock outstanding as of the close of business on October 31, 2021: 2,525,943,936

-- 1 of 59 --

Table of Contents
Page No.
PART I 	FINANCIAL INFORMATION 	3
Item 1. 	Financial Statements 	3
Condensed Consolidated Statement of Income 	3
Condensed Consolidated Statement of Comprehensive Income 	3
Condensed Consolidated Balance Sheet 	4
Condensed Consolidated Statement of Cash Flows 	5
Notes to Condensed Consolidated Financial Statements 	6
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	35
Item 3. 	Quantitative and Qualitative Disclosures about Market Risk 	52
Item 4. 	Controls and Procedures 	52
Cautionary Factors That May Affect Future Results 	52
PART II 	OTHER INFORMATION 	53
Item 1. 	Legal Proceedings 	53
Item 1A. 	Risk Factors 	53
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds 	53
Item 6. 	Exhibits 	54
Signatures 	55

-- 2 of 59 --

Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
Three Months Ended
September 30, Nine Months Ended
September 30,
2021 	2020 	2021 	2020
Sales 	$ 	13,154 	$ 	10,929 	$ 	35,183 	$ 	30,570
Costs, Expenses and Other
Cost of sales 	3,450 	3,013 	9,752 	8,589
Selling, general and administrative 	2,336 	2,060 	6,804 	6,336
Research and development 	2,445 	3,349 	9,177 	7,609
Restructuring costs 	107 	113 	487 	265
Other (income) expense, net 	(450) 	(312) 	(1,007) 	(637)
7,888 	8,223 	25,213 	22,162
Income from Continuing Operations Before Taxes 	5,266 	2,706 	9,970 	8,408
Taxes on Income from Continuing Operations 	695 	380 	1,436 	1,271
Net Income from Continuing Operations 	4,571 	2,326 	8,534 	7,137
Less: Net Income Attributable to Noncontrolling Interests 	4 	2 	9 	1
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 	4,567 	2,324 	8,525 	7,136
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to
Noncontrolling Interests 	— 	617 	766 	2,025
Net Income Attributable to Merck & Co. Inc. 	$ 	4,567 	$ 	2,941 	$ 	9,291 	$ 	9,161
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common
Shareholders:
Income from Continuing Operations 	$ 	1.81 	$ 	0.92 	$ 	3.37 	$ 	2.82
Income from Discontinued Operations 	— 	0.24 	0.30 	0.80
Net Income 	$ 	1.81 	$ 	1.16 	$ 	3.67 	$ 	3.62
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc.
Common Shareholders:
Income from Continuing Operations 	$ 	1.80 	$ 	0.92 	$ 	3.36 	$ 	2.81
Income from Discontinued Operations 	— 	0.24 	0.30 	0.80
Net Income 	$ 	1.80 	$ 	1.16 	$ 	3.66 	$ 	3.61
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
Three Months Ended
September 30, Nine Months Ended
September 30,
2021 	2020 	2021 	2020
Net Income Attributable to Merck & Co., Inc. 	$ 	4,567 	$ 	2,941 	$ 	9,291 	$ 	9,161
Other Comprehensive Income (Loss) Net of Taxes:
Net unrealized gain (loss) on derivatives, net of reclassifications 	84 	(137) 	324 	(153)
Net unrealized loss on investments, net of reclassifications 	— 	— 	— 	(18)
Benefit plan net gain and prior service credit, net of amortization 	38 	62 	1,522 	161
Cumulative translation adjustment 	(84) 	85 	(251) 	(180)
38 	10 	1,595 	(190)
Comprehensive Income Attributable to Merck & Co., Inc. 	$ 	4,605 	$ 	2,951 	$ 	10,886 	$ 	8,971
The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -

-- 3 of 59 --

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
September 30,
2021 	December 31, 2020
Assets
Current Assets
Cash and cash equivalents 	$ 	10,016 	$ 	8,050
Accounts receivable (net of allowance for doubtful accounts of $69 in 2021
and $67 in 2020) 	8,571 	6,803
Inventories (excludes inventories of $2,373 in 2021 and $2,070 in 2020
classified in Other assets - see Note 7) 	5,603 	5,554
Other current assets 	6,868 	4,674
Current assets of discontinued operations 	— 	2,683
Total current assets 	31,058 	27,764
Investments 	435 	785
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,155
in 2021 and $18,162 in 2020 	18,565 	17,000
Goodwill 	18,862 	18,882
Other Intangibles, Net 	13,384 	14,101
Other Assets 	11,190 	9,881
Noncurrent Assets of Discontinued Operations 	— 	3,175
$ 	93,494 	$ 	91,588
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt 	$ 	3,534 	$ 	6,431
Trade accounts payable 	3,366 	4,327
Accrued and other current liabilities 	14,214 	12,212
Income taxes payable 	954 	1,597
Dividends payable 	1,660 	1,674
Current liabilities of discontinued operations 	— 	1,086
Total current liabilities 	23,728 	27,327
Long-Term Debt 	22,907 	25,360
Deferred Income Taxes 	1,527 	1,005
Other Noncurrent Liabilities 	9,469 	12,306
Noncurrent Liabilities of Discontinued Operations 	— 	186
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2021 and 2020 	1,788 	1,788
Other paid-in capital 	44,149 	39,588
Retained earnings 	51,691 	47,362
Accumulated other comprehensive loss 	(4,590) 	(6,634)
93,038 	82,104
Less treasury stock, at cost:
1,051,780,149 shares in 2021 and 1,046,877,695 shares in 2020 	57,244 	56,787
Total Merck & Co., Inc. stockholders’ equity 	35,794 	25,317
Noncontrolling Interests 	69 	87
Total equity 	35,863 	25,404
$ 	93,494 	$ 	91,588
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -

-- 4 of 59 --

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
Nine Months Ended
September 30,
2021 	2020
Cash Flows from Operating Activities
Net income from continuing operations 	$ 	8,534 	$ 	7,137
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Amortization 	1,231 	1,393
Depreciation 	1,148 	1,210
Intangible asset impairment charges 	— 	35
Income from investments in equity securities, net 	(1,535) 	(964)
Charge for the acquisition of Pandion Therapeutics, Inc. 	1,556 	—
Deferred income taxes 	28 	32
Share-based compensation 	360 	329
Other 	499 	519
Net changes in assets and liabilities 	(3,794) 	(5,484)
Net Cash Provided by Operating Activities from Continuing Operations 	8,027 	4,207
Cash Flows from Investing Activities
Capital expenditures 	(3,240) 	(2,998)
Purchases of securities and other investments 	(1) 	(78)
Proceeds from sales of securities and other investments 	497 	1,894
Acquisition of Pandion Therapeutics, Inc. net of cash acquired 	(1,554) 	—
Acquisition of ArQule, Inc., net of cash acquired 	— 	(2,545)
Other acquisitions, net of cash acquired 	(89) 	(907)
Other 	15 	138
Net Cash Used in Investing Activities from Continuing Operations 	(4,372) 	(4,496)
Cash Flows from Financing Activities
Net change in short-term borrowings 	(3,983) 	(311)
Payments on debt 	(1,153) 	(1,954)
Distribution from Organon & Co. 	9,000 	—
Proceeds from issuance of debt 	— 	4,419
Purchases of treasury stock 	(822) 	(1,281)
Dividends paid to stockholders 	(4,967) 	(4,673)
Proceeds from exercise of stock options 	68 	68
Other 	(253) 	(472)
Net Cash Used in Financing Activities from Continuing Operations 	(2,110) 	(4,204)
Discontinued Operations
Net cash provided by operating activities 	1,051 	2,040
Net cash used in investing activities 	(134) 	(169)
Net cash used in financing activities 	(504) 	—
Net Cash Flows Provided by Discontinued Operations 	413 	1,871
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 	(65) 	89
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 	1,893 	(2,533)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted
cash of $103 at January 1, 2021 included in Other Assets) 	8,153 	9,934
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash
of $30 at September 30, 2021 included in Other Assets) 	$ 	10,046 	$ 	7,401
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -

-- 5 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited)
1. 	Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant
to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in
the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction
with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2021.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all
adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Reclassifications — 	Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The
established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the
rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The
historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off have been reflected as
discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2).
Recently Adopted Accounting Standards
In December 2019, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting and reporting of income taxes. The
guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities,
clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination, and reflecting enacted changes in tax laws or rates
in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s consolidated financial
statements upon adoption.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity
method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring
certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to
the Company’s consolidated financial statements upon adoption.
Recently Issued Accounting Standards Not Yet Adopted
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on
financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts,
hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued
because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020
through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In August 2020, the FASB issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The
guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity
as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The amended guidance is effective for interim and annual
periods in 2022. Early adoption is permitted. The application of the amendments in the new guidance are to be applied either on a modified retrospective or a
retrospective basis. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a
business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is
to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The Company is currently
evaluating the impact of adoption on its consolidated financial statements.
- 6 -

-- 6 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited)
2. Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In
connection with the spin-off, each Merck shareholder received one tenth of a share of Organon’s common stock for each share of Merck common stock held by
such shareholder. The distribution is expected to qualify as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion
principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the
obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.
Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other
agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services
agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters
agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly,
Organon will provide Merck various services. The provision of services under the TSA agreement generally will terminate within 25 months following the spin-
off. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits
and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck will continue to market, import and
distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance
with the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the
economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture
and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture and supply certain formulated pharmaceutical products for Organon, and (c)
package and label certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which
Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical
products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
Amounts included in the condensed consolidated statement of income for the above agreements were immaterial in the third quarter and first nine
months of 2021. The amount due from Organon under the above agreements was $1.4 billion at September 30, 2021 and is reflected in 	Other current assets. The
amount due to Organon under these agreements was $930 million at September 30, 2021 and is included in Accrued and other current liabilities.
The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were
contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the
Company’s condensed consolidated statement of income as 	Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling
Interests 	through June 2, 2021, the date of the spin-off. Prior periods have been recast to reflect this presentation. As a result of the spin-off of Organon, Merck
incurred separation costs of $556 million in the nine months ended September 30, 2021, and $193 million and $483 million in the three and nine months ended
September 30, 2020, respectively, which are also included in 	Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling
Interests. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as
investment banking fees. As of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued
operations in the condensed consolidated balance sheet.
- 7 -

-- 7 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited)
Details of 	Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 	are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions) 	2020 	2021 	2020
Sales 	$ 	1,622 	$ 	2,512 	$ 	4,911
Costs, Expenses and Other
Cost of sales 	468 	789 	1,362
Selling, general and administrative 	390 	877 	1,046
Research and development 	41 	103 	113
Restructuring costs 	1 	1 	4
Other (income) expense, net 	— 	(15) 	7
900 	1,755 	2,532
Income from discontinued operations before taxes 	722 	757 	2,379
Tax provision (benefit) 	103 	(12) 	343
Income from discontinued operations, net of taxes 	619 	769 	2,036
Less: Income of discontinued operations attributable to noncontrolling interests 	2 	3 	11
Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests 	$ 	617 	$ 	766 	$ 	2,025
Reflects amounts through the June 2, 2021 spin-off date.
Details of assets and liabilities of discontinued operations are as follows:
($ in millions) 	December 31, 2020
Cash and cash equivalents 	$ 	12
Accounts receivable, less allowance for doubtful accounts 	1,048
Inventories 	756
Other current assets 	867
Current assets of discontinued operations 	$ 	2,683
Property, plant and equipment, net 	$ 	986
Goodwill 	1,356
Other intangibles, net 	503
Other assets 	330
Noncurrent Assets of Discontinued Operations 	$ 	3,175
Trade accounts payable 	$ 	267
Accrued and other current liabilities 	841
Income taxes payable 	(22)
Total current liabilities of discontinued operations 	$ 	1,086
Deferred income taxes 	$ 	10
Other noncurrent liabilities 	176
Noncurrent Liabilities of Discontinued Operations 	$ 	186
As a result of the spin-off of Organon, Merck distributed net liabilities of $5.1 billion as of June 2, 2021 consisting of debt of $9.4 billion (described
above), goodwill of $1.4 billion, property, plant and equipment of $981 million, cash of $929 million, inventory of $815 million, other intangibles, net, of
$519 million and other net liabilities of $328 million. The spin-off also resulted in a net decrease to 	Accumulated other comprehensive loss 	(AOCL) of $449 million
consisting of $421 million for the derecognition of net losses on foreign currency translation adjustments and $28 million associated with employee benefit plans.
The distribution of the net liabilities and reduction to 	AOCL 	resulted in a net $4.6 billion increase to 	Other paid-in capital.
(1)
(1)
- 8 -

-- 8 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited)
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs)
to certain management level employees. In addition, employees and non-employee directors were granted options to purchase shares of Company common stock
at the fair market value at the time of grant. In connection with the spin-off of Organon, all outstanding Merck stock options, RSUs and PSUs (whether vested or
unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards
preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Approximately 1.3
million RSUs, 1.9 million stock options and 248 thousand PSUs were converted from Merck awards into Organon awards.
Expenses for curtailments, settlements and termination benefits provided to certain employees were incurred in connection with the spin-off.
Additionally, the transfer of employees to Organon triggered remeasurements of some of the Company’s pension plans (see Note 11).
3. 	Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to
complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third
party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development.
The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its
portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial
results of the acquired entity are not significant when compared with the Company’s financial results.
In September 2021, Merck and Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, entered into a definitive agreement
under which Merck will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. Acceleron is focused on harnessing the
power of the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and
repair. Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical
outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as add-on to current standard of care for the treatment of PAH. In
addition to sotatercept, Acceleron’s portfolio includes Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation recombinant fusion protein approved in
the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders. Reblozyl is being developed and commercialized through a
global collaboration with Bristol Myers Squibb. Under the terms of the acquisition agreement, Merck, through a subsidiary, initiated a tender offer to acquire all
outstanding shares of Acceleron. The closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the
total number of Acceleron’s outstanding shares, receipt of applicable regulatory approvals, and other customary conditions. 	The acquisition agreement includes
termination provisions providing that (i) in the event Acceleron terminates in order to enter into an agreement with respect to a superior proposal (as defined in the
agreement), Acceleron will be required to pay a termination fee of $345 million, and (ii) in the event the acquisition is not consummated due to antitrust conditions,
Merck will be required to pay Acceleron a reverse termination fee of $650 million to $750 million depending on the time of termination. 	The transaction is
expected to close in the fourth quarter of 2021.
In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to
address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune
control nodes. Total consideration paid of $1.9 billion included $147 million of transaction costs primarily comprised of share-based compensation payments to
settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and 	Research and
development 	expenses of $1.7 billion in the first nine months of 2021 related to the transaction. There are no future contingent payments associated with the
acquisition.
In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in
HIV that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead’s investigational capsid inhibitor,
lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with
other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.
Under the terms of the agreement, Gilead and Merck will share operational responsibilities, as well as development, commercialization and marketing
costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable
formulation programs. For long-acting oral products, Gilead
- 9 -

-- 9 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will
lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and
certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation
revenue tiers. Upon passing $2.0 billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any
revenues above the threshold. Upon passing $3.5 billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and
35% Merck for any revenues above the threshold.
Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck’s
investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead’s
investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase
inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will
split development costs and revenues, unless the non-exercising company decides to opt-out.
In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover,
develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three
different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including
regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in 	Research and
development 	expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront
payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is
eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to: $217.5 million in developmental
milestones, $570 million in regulatory milestones, and $1.05 billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties
ranging from 7% to 14% on future sales.
In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million.
OncoImmune’s lead therapeutic candidate MK-7110 (formerly known as CD24Fc) was being evaluated for the treatment of patients hospitalized with coronavirus
disease 2019 (COVID-19). The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition,
OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In
connection with the closing of the acquisition, Merck invested $50 million for a 20% ownership interest in the new entity, which was valued at $33 million
resulting in a $17 million premium. Merck also recognized other net liabilities of $22 million. The Company recorded 	Research and development 	expenses of
$462 million in 2020 related to this transaction. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would
be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the
first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized
with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines,
Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of
$207 million in the first nine months of 2021, which are reflected in 	Cost of sales 	and relate to fixed-asset and materials write-offs, as well as the recognition of
liabilities for purchase commitments.
In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally
develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2
clinical trials. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with
Keytruda 	(pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will
equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in
5 million shares of Seagen common stock at a price of $200 per share. Merck recorded $622 million in 	Research and development 	expenses in the third quarter and
first nine months of 2020 related to this transaction reflecting the upfront payment as well as a $22 million mark-to-market loss on the purchase commitment
(forward contract) relating to the equity shares (calculated based on the closing price of Seagen common stock on September 30, 2020). The closing of the equity
investment occurred in October 2020 and resulted in the recognition of a $6 million reduction to 	Research and development 	expenses based on the price of Seagen
common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6 billion, including $850 million in
development milestones and $1.75 billion in sales-based milestones.
Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine
kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-
- 10 -

-- 10 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing
applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the
Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and
other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated
regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210 million, which were recorded as
Research and development 	expenses in the third quarter and first nine months of 2020. Seagen is also eligible to receive future contingent regulatory approval
milestones of up to $65 million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck’s territories.
Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical
Company Limited for €256 million ($302 million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment
of $289 million and other net assets of $13 million. There are no future contingent payments associated with the acquisition.
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel
products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets
of $401 million related to currently marketed products and inventory of $9 million at the acquisition date. The estimated fair values of the identifiable intangible
assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The
intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments
associated with the acquisition.
Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement
to develop molnupiravir (MK-4482/EIDD-2801) an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19.
Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio
received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory
approval milestones. Any profits from the collaboration will be split between the partners equally. Merck and Ridgeback Bio are committed to ensure that any
medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.
In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine
candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make
additional contingent payments of up to $740 million. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of
the contingent consideration was $85 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate
dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for in-process research and development (IPR&D) of $113
million, cash of $59 million, deferred tax assets of $72 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair
value of net assets acquired of $239 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The
fair values of the identifiable intangible assets related to IPR&D were determined using an income approach. Actual cash flows are likely to be different than those
assumed. In January 2021, the Company announced it was discontinuing development of V591. As a result, in the fourth quarter of 2020, the Company recorded an
IPR&D impairment charge of $90 million within 	Research and development 	expenses. The Company also recorded a reduction in 	Research and development
expenses resulting from a decrease in the related liability for contingent consideration of $45 million since future contingent milestone payments have been reduced
to $450 million in the aggregate, including up to $60 million for development milestones, up to $196 million for regulatory approval milestones, and up to
$194 million for commercial milestones.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and
development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based
compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company
incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle
non-vested equity awards attributable to postcombination service. These costs were included in 	Selling, general and administrative 	expenses in the first nine
months of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor
currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as an acquisition of a business.
- 11 -

-- 11 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
($ in millions) 	January 16, 2020
Cash and cash equivalents 	$ 	145
IPR&D MK-1026 (formerly ARQ 531) 	2,280
Licensing arrangement for ARQ 087 	80
Deferred income tax liabilities 	(361)
Other assets and liabilities, net 	34
Total identifiable net assets 	2,178
Goodwill 	512
Consideration transferred 	$ 	2,690
The estimated fair value of the identifiable intangible asset related to IPR&D was determined using an income approach. The future net cash flows were discounted to present value utilizing
a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed.
The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
4. 	Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with
its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial
success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. For further details refer to Note 4 to the
consolidated financial statements included in Merck’s 2020 Form 10‑K.
AstraZeneca
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize
AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations
with their respective PD-1 and PD-L1 medicines, 	Keytruda 	and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo
(selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for
Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the
principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization
costs, as alliance revenue and its share of development costs associated with the collaboration as part of 	Research and development 	expenses. Reimbursements
received from AstraZeneca for research and development expenses are recognized as reductions to 	Research and development 	costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options.
In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and
regulatory milestones. As of September 30, 2021, sales-based milestone payments accrued but not yet paid totaled $400 million. Potential future sales-based
milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. Additionally, potential future
regulatory milestone payments of $1.4 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at
September 30, 2021 and is included in 	Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected
future cash flows, subject to impairment testing.
(1)
(2)
(1)
(2)
- 12 -

-- 12 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Alliance revenue - Lynparza 	$ 	246 	$ 	196 	$ 	721 	$ 	519
Alliance revenue - Koselugo 	6 	3 	20 	3
Total alliance revenue 	$ 	252 	$ 	199 	$ 	741 	$ 	522
Cost of sales 	42 	41 	125 	205
Selling, general and administrative 	44 	40 	127 	112
Research and development 	27 	20 	87 	93
($ in millions) September 30,
2021 December 31,
2020
Receivables from AstraZeneca included in 	Other current assets 	$ 	248 	$ 	215
Payables to AstraZeneca included in 	Accrued and other current liabilities 	415 	423
Represents amortization of capitalized milestone payments.
Includes accrued milestone payments.
Eisai
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima
(lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima
jointly, both as monotherapy and in combination with 	Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales
transactions), and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization
costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected
in 	Research and development 	expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs
incurred in excess of agreed upon caps and costs related to certain combination studies of 	Keytruda 	and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain options rights (of which the
final $125 million option payment was made in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related
to the successful achievement of sales-based and regulatory milestones. Merck made sales-based milestone payments of $200 million to Eisai in the first nine
months of 2021. As of September 30, 2021, sales-based milestone payments accrued but not yet paid totaled $600 million. Potential future sales-based milestone
payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the third quarter of 2021, Lenvima
received a regulatory approval triggering a capitalized milestone payment of $75 million from Merck to Eisai. Potential future regulatory milestone payments of
$50 million remain under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.0 billion at
September 30, 2021 and is included in 	Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected
future cash flows, subject to impairment testing.
(1)
(2)
(1)
(2)
- 13 -

-- 13 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Alliance revenue - Lenvima 	$ 	188 	$ 	142 	$ 	498 	$ 	421
Cost of sales 	49 	46 	143 	215
Selling, general and administrative 	34 	18 	88 	48
Research and development 	43 	48 	165 	168
($ in millions) September 30,
2021 December 31,
2020
Receivables from Eisai included in 	Other current assets 	$ 	223 	$ 	157
Payables to Eisai included in 	Accrued and other current liabilities 	600 	335
Payables to Eisai included in 	Other Noncurrent Liabilities 	— 	600
Represents amortization of capitalized milestone payments.
Includes accrued milestone and future option payments.
Includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate
cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The
collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in
July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck
commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales
of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales in Bayer’s
marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s
marketing territories.
In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In
the first quarter of 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future
would trigger the remaining $400 million sales-based milestone payment that was outstanding under this agreement. Accordingly, Merck recorded a liability of
$400 million and a corresponding increase to the intangible assets related to this collaboration. Merck also recognized $153 million of cumulative amortization
expense related to the recognition of this milestone in the first nine months of 2021.
The intangible asset balance related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone
payments attributed to Adempas) was $869 million at September 30, 2021 and is being amortized over its estimated useful life through 2027 as supported by
projected future cash flows, subject to impairment testing. The intangible asset balance related to Verquvo (which reflects the portion of the final sales-based
milestone payment that was attributed to Verquvo) was $72 million at September 30, 2021 and is being amortized over its estimated useful life through 2031 as
supported by projected future cash flows, subject to impairment testing.
(1)
(2)
(3)
(1)
(2)
(3)
- 14 -

-- 14 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Alliance revenue - Adempas/Verquvo 	$ 	100 	$ 	83 	$ 	248 	$ 	216
Net sales of Adempas recorded by Merck 	59 	55 	188 	167
Net sales of Verquvo recorded by Merck 	2 	— 	3 	—
Total sales 	$ 	161 	$ 	138 	$ 	439 	$ 	383
Cost of sales 	53 	81 	328 	229
Selling, general and administrative 	31 	12 	84 	32
Research and development 	16 	12 	36 	53
($ in millions) September 30,
2021 December 31,
2020
Receivables from Bayer included in 	Other current assets 	$ 	139 	$ 	65
Payables to Bayer included in 	Accrued and other current liabilities 	467 	—
Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization as noted above. In addition, cost of sales in all periods
now includes Bayer’s share of profits from sales in Merck’s marketing territories.
Includes accrued milestone payment.
5. 	Restructuring
In 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing
the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant
rationalization, builds on prior restructuring programs and does not include any actions associated with the spin-off of Organon. As the Company continues to
evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further
actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the
cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.0 billion. The Company estimates that
approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs.
Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
The Company recorded total pretax costs of $168 million and $185 million in the third quarter of 2021 and 2020, respectively, and $630 million and
$500 million for the first nine months of 2021 and 2020, respectively, related to restructuring program activities. Since inception of the Restructuring Program
through September 30, 2021, Merck has recorded total pretax accumulated costs of approximately $2.4 billion. For the full year of 2021, the Company expects to
record charges of approximately $700 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
Three Months Ended September 30, 2021 	Nine Months Ended September 30, 2021
($ in millions) Separation
Costs Accelerated
Depreciation 	Other 	Total Separation
Costs Accelerated
Depreciation 	Other 	Total
Cost of sales 	$ 	— 	$ 	11 	$ 	37 	$ 	48 	$ 	— 	$ 	32 	$ 	81 	$ 	113
Selling, general and administrative 	— 	4 	1 	5 	— 	8 	1 	9
Research and development 	— 	7 	1 	8 	— 	20 	1 	21
Restructuring costs 	17 	— 	90 	107 	310 	— 	177 	487
$ 	17 	$ 	22 	$ 	129 	$ 	168 	$ 	310 	$ 	60 	$ 	260 	$ 	630
Three Months Ended September 30, 2020 	Nine Months Ended September 30, 2020
($ in millions) Separation
Costs Accelerated
Depreciation 	Other 	Total Separation
Costs Accelerated
Depreciation 	Other 	Total
Cost of sales 	$ 	— 	$ 	33 	$ 	5 	$ 	38 	$ 	— 	$ 	89 	$ 	42 	$ 	131
Selling, general and administrative 	— 	15 	— 	15 	— 	37 	— 	37
Research and development 	— 	18 	1 	19 	— 	66 	1 	67
Restructuring costs 	61 	— 	52 	113 	143 	— 	122 	265
$ 	61 	$ 	66 	$ 	58 	$ 	185 	$ 	143 	$ 	192 	$ 	165 	$ 	500
(1)
(2)
(1)
(2)
- 15 -

-- 15 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably
estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the
programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based
upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to
the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are
sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure
dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2021 and 2020 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from
the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit
plans (see Note 11) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2021:
($ in millions) Separation
Costs Accelerated
Depreciation 	Other 	Total
Restructuring reserves January 1, 2021 	$ 	567 	$ 	— 	$ 	19 	$ 	586
Expense 	310 	60 	260 	630
(Payments) receipts, net 	(305) 	— 	(155) 	(460)
Non-cash activity 	— 	(60) 	(84) 	(144)
Restructuring reserves September 30, 2021 	$ 	572 	$ 	— 	$ 	40 	$ 	612
The remaining cash outlays are expected to be substantially completed by the end of 2023.
6. 	Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets
and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and
accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of
future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar
value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the
Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are
expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of
forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit
profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company
manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated
Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or 	Other comprehensive income 	(OCI),
depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash
flow hedges, the unrealized gains or losses on these contracts are recorded in 	AOCL 	and reclassified into 	Sales 	when the hedged anticipated revenue is recognized.
For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in
Sales 	each period. The cash flows from both designated and non-
(1)
(1)
- 16 -

-- 16 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for
trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary
assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a
currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward
exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For
exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is
deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the
hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect
on the balance sheet date with the effects of changes in spot rates reported in 	Other (income) expense, net. The forward contracts are not designated as hedges and
are marked to market through 	Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the
remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences
are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates.
The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in
foreign currency translation adjustment within 	OCI 	and remain in 	AOCL 	until either the sale or complete or substantially complete liquidation of the subsidiary.
The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components).
Changes in fair value of the excluded components are recognized in 	OCI. The Company recognizes in earnings the initial value of the excluded components on a
straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as
investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been
designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to
spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within 	OCI.
The effects of the Company’s net investment hedges on 	OCI 	and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other
Comprehensive Income
Amount of Pretax (Gain) Loss Recognized in 	Other
(income) expense, net 	for Amounts Excluded from
Effectiveness Testing
Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Net Investment Hedging Relationships
Foreign exchange contracts 	$ 	1 	$ 	10 	$ 	(27) 	$ 	15 	$ 	(4) 	$ 	(4) 	$ 	(12) 	$ 	(15)
Euro-denominated notes 	(77) 	162 	(199) 	182 	— 	— 	— 	—
No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes
and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that
would put principal capital at risk.
In January 2021, five interest rate swaps with a total notional amount of $1.15 billion matured. These swaps effectively converted the Company’s $1.15
billion, 3.875% fixed-rate notes due 2021 to variable rate debt. At September 30, 2021, the Company was a party to nine pay-floating, receive-fixed interest rate
swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the
table below.
(1)
(1)
- 17 -

-- 17 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
September 30, 2021
($ in millions) 	Par Value of Debt Number of Interest Rate
Swaps Held Total Swap Notional
Amount
2.40% notes due 2022 	$ 	1,000 	4 	$ 	1,000
2.35% notes due 2022 	1,250 	5 	1,250
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate.
The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in
the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The table below presents the location of amounts recorded on the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for
fair value hedges:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging
Adjustment Increase (Decrease) Included in the
Carrying Amount
($ in millions) 	September 30, 2021 	December 31, 2020 	September 30, 2021 	December 31, 2020
Loans payable and current portion of long-term debt 	$ 	2,274 	$ 	1,150 	$ 	25 	$ 	—
Long-Term Debt 	— 	2,301 	— 	53
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging
instruments and those that are not designated as hedging instruments:
September 30, 2021 	December 31, 2020
Fair Value of Derivative 	U.S. Dollar
Notional
Fair Value of Derivative 	U.S. Dollar
Notional	($ in millions) 	Asset 	Liability 	Asset 	Liability
Derivatives Designated as Hedging
Instruments 	Balance Sheet Caption
Interest rate swap contracts 	Other current assets 	$ 	26 	$ 	— 	$ 	2,250 	$ 	1 	$ 	— 	$ 	1,150
Interest rate swap contracts 	Other Assets 	— 	— 	— 	54 	— 	2,250
Foreign exchange contracts 	Other current assets 	224 	— 	7,138 	12 	— 	3,183
Foreign exchange contracts 	Other Assets 	45 	— 	1,469 	45 	— 	2,030
Foreign exchange contracts 	Accrued and other current liabilities 	— 	15 	1,601 	— 	217 	5,049
Foreign exchange contracts 	Other Noncurrent Liabilities 	— 	1 	145 	— 	1 	52
$ 	295 	$ 	16 	$ 	12,603 	$ 	112 	$ 	218 	$ 	13,714
Derivatives Not Designated as
Hedging Instruments 	Balance Sheet Caption
Foreign exchange contracts 	Other current assets 	$ 	82 	$ 	— 	$ 	6,333 	$ 	70 	$ 	— 	$ 	7,260
Foreign exchange contracts 	Accrued and other current liabilities 	— 	117 	9,522 	— 	307 	11,810
$ 	82 	$ 	117 	$ 	15,855 	$ 	70 	$ 	307 	$ 	19,070
$ 	377 	$ 	133 	$ 	28,458 	$ 	182 	$ 	525 	$ 	32,784
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting
agreements with several of its financial institution counterparties (see 	Concentrations of Credit Risk 	below). The following table provides information on the
Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by
counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
September 30, 2021 	December 31, 2020
($ in millions) 	Asset 	Liability 	Asset 	Liability
Gross amounts recognized in the condensed consolidated balance sheet 	$ 	377 	$ 	133 	$ 	182 	$ 	525
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet 	(120) 	(120) 	(156) 	(156)
Cash collateral received/posted 	(65) 	— 	— 	(36)
Net amounts 	$ 	192 	$ 	13 	$ 	26 	$ 	333
- 18 -

-- 18 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow
hedging relationships (including amounts attributable to discontinued operations):
Sales
Other (income) expense,
net
Other comprehensive
income (loss) 	Sales 	Other (income) expense, net 	Other comprehensive
income (loss)
Three Months Ended
September 30,
Three Months Ended
September 30,
Three Months Ended
September 30,
Nine Months Ended
September 30,
Nine Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Financial Statement Line Items in which
Effects of Fair Value or Cash Flow Hedges
are Recorded 	$ 	13,154 	$ 	10,929 	$ 	(450) 	$ 	(312) 	$ 	38 	$ 	10 	$ 	35,183 	$ 	30,570 	$ 	(1,007) 	$ 	(637) 	$ 	1,595 	$ 	(190)
(Gain) loss on fair value hedging
relationships
Interest rate swap contracts
Hedged items 	— 	— 	(9) 	(14) 	— 	— 	— 	— 	(29) 	54 	— 	—
Derivatives designated as hedging
instruments 	— 	— 	(1) 	— 	— 	— 	— 	— 	(1) 	(76) 	— 	—
Impact of cash flow hedging relationships
Foreign exchange contracts
Amount of gain (loss) recognized in 	OCI
on derivatives 	— 	— 	— 	— 	72 	(195) 	— 	— 	— 	— 	193 	(126)
(Decrease) increase in 	Sales 	as a result of
AOCL 	reclassifications 	(36) 	(23) 	— 	— 	36 	23 	(219) 	65 	— 	— 	219 	(65)
Interest rate contracts
Amount of gain recognized in 	Other
(income) expense, net 	on derivatives 	— 	— 	— 	(1) 	— 	— 	— 	— 	(2) 	(3) 	— 	—
Amount of loss recognized in 	OCI 	on
derivatives 	— 	— 	— 	— 	— 	(1) 	— 	— 	— 	— 	(2) 	(3)
Interest expense is a component of 	Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments (including amounts
attributable to discontinued operations):
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Derivatives Not Designated as Hedging Instruments 	Income Statement Caption
Foreign exchange contracts 	Other (income) expense, net 	$ 	18 	$ 	(7) 	$ 	234 	$ 	(138)
Foreign exchange contracts 	Sales 	(4) 	7 	6 	4
Interest rate contracts 	Other (income) expense, net 	— 	— 	— 	9
Forward contract related to Seagen common stock 	Research and development 	— 	22 	— 	22
These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency
exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.
These derivative contracts serve as economic hedges of forecasted transactions.
These derivative contracts serve as economic hedges against rising treasury rates.
At September 30, 2021, the Company estimates $55 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge
foreign currency denominated sales over that same period will be reclassified from 	AOCL 	to 	Sales. The amount ultimately reclassified to 	Sales 	may differ as
foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.
(1) 	(1)
(1)
(1)
(2)
(3)
(1)
(2)
(3)
- 19 -

-- 19 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
September 30, 2021 	December 31, 2020
Amortized
Cost
Gross Unrealized 	Fair
Value Amortized
Cost
Gross Unrealized 	Fair
Value	($ in millions) 	Gains 	Losses 	Gains 	Losses
U.S. government and agency securities 	$ 	83 	$ 	— 	$ 	— 	$ 	83 	$ 	84 	$ 	— 	$ 	— 	$ 	84
Corporate notes and bonds 	4 	— 	— 	4 	— 	— 	— 	—
Foreign government bonds 	2 	— 	— 	2 	5 	— 	— 	5
Total debt securities 	$ 	89 	$ 	— 	$ 	— 	$ 	89 	$ 	89 	$ 	— 	$ 	— 	$ 	89
Publicly traded equity securities 	1,915 	1,787
Total debt and publicly traded equity securities 	$ 	2,004 	$ 	1,876
Unrealized net gains of $90 million and unrealized net losses of $109 million were recorded in 	Other (income) expense, net 	on equity securities still held at September 30, 2021 in the third
quarter and first nine months of 2021, respectively. Unrealized net gains recorded in 	Other (income) expense, net 	on equity securities still held at September 30, 2020 were $43 million and
$512 million in the third quarter and first nine months of 2020, respectively.
At September 30, 2021 and September 30, 2020, the Company also had $578 million and $508 million, respectively, of equity investments without
readily determinable fair values included in 	Other Assets. The Company recognizes unrealized gains on these equity investments based on favorable observable
price changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price
changes. During the first nine months 	of 2021, 	the Company recorded unrealized gains of $104 million and unrealized losses of $1 million in 	Other (income)
expense, net 	related to these equity investments held at September 30, 2021. During the first nine months 	of 2020, 	the Company recorded unrealized gains of
$21 million and unrealized losses of $3 million in 	Other (income) expense, net 	related to these equity investments held at September 30, 2020. Cumulative
unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair
values still held at September 30, 2021 were $229 million and $7 million, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most
advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value
hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs
used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: 	Level 1 	- Quoted prices (unadjusted) in active markets for
identical assets or liabilities; 	Level 2 	- Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are
observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; 	Level 3 	- Unobservable inputs that are
supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow
methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires
significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the
categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
(1)
(1)
- 20 -

-- 20 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements Using 	Fair Value Measurements Using
Level 1 	Level 2 	Level 3 	Total 	Level 1 	Level 2 	Level 3 	Total
($ in millions) 	September 30, 2021 	December 31, 2020
Assets
Investments
Foreign government bonds 	$ 	— 	$ 	2 	$ 	— 	$ 	2 	$ 	— 	$ 	5 	$ 	— 	$ 	5
Publicly traded equity securities 	433 	— 	— 	433 	780 	— 	— 	780
433 	2 	— 	435 	780 	5 	— 	785
Other assets
U.S. government and agency securities 	83 	— 	— 	83 	84 	— 	— 	84
Corporate notes and bonds 	4 	— 	— 	4 	— 	— 	— 	—
Publicly traded equity securities 	1,482 	— 	— 	1,482 	1,007 	— 	— 	1,007
1,569 	— 	— 	1,569 	1,091 	— 	— 	1,091
Derivative assets
Forward exchange contracts 	— 	230 	— 	230 	— 	90 	— 	90
Purchased currency options 	— 	121 	— 	121 	— 	37 	— 	37
Interest rate swaps 	— 	26 	— 	26 	— 	55 	— 	55
— 	377 	— 	377 	— 	182 	— 	182
Total assets 	$ 	2,002 	$ 	379 	$ 	— 	$ 	2,381 	$ 	1,871 	$ 	187 	$ 	— 	$ 	2,058
Liabilities
Other liabilities
Contingent consideration 	$ 	— 	$ 	— 	$ 	902 	$ 	902 	$ 	— 	$ 	— 	$ 	841 	$ 	841
Derivative liabilities
Forward exchange contracts 	— 	132 	— 	132 	— 	505 	— 	505
Written currency options 	— 	1 	— 	1 	— 	20 	— 	20
— 	133 	— 	133 	— 	525 	— 	525
Total liabilities 	$ 	— 	$ 	133 	$ 	902 	$ 	1,035 	$ 	— 	$ 	525 	$ 	841 	$ 	1,366
Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not
significant.
As of September 30, 2021 and December 31, 2020, 	Cash and cash equivalents 	included $9.2 billion and $6.8 billion of cash equivalents, respectively
(which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business acquisitions is as
follows:
Nine Months Ended September 30,
($ in millions) 	2021 	2020
January 1 	$ 	841 	$ 	767
Additions 	— 	97
Changes in estimated fair value 	73 	71
Payments 	— 	(106)
Other 	(12) 	—
September 30 	$ 	902 	$ 	829
Recorded in 	Cost of sales, Research and development 	expenses, and 	Other (income) expense, net. Includes cumulative translation adjustments.
Balance at September 30, 2021 includes $289 million recorded as a current liability for amounts expected to be paid within the next 12 months.
At September 30, 2021 and December 31, 2020, $747 million and $711 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As
part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through
December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value
the cash flows.
The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 3). The payments of contingent consideration in 2020
relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.
(1)
(2)
(2)
(1)
(2)
(1)
(2)(3)
(1)
(2)
(3)
- 21 -

-- 21 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying
value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2021, was $29.1 billion compared with a
carrying value of $26.4 billion and at December 31, 2020, was $36.0 billion compared with a carrying value of $31.8 billion. Fair value was estimated using recent
observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial
institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and
investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers
and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial performance
and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global
economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company
factored $2.4 billion and $2.1 billion of accounts receivable at September 30, 2021 and December 31, 2020, respectively, under these factoring arrangements,
which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated
Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored
receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated
Statement of Cash Flows. The cost of factoring such accounts receivable was 	de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with
several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be
exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral
received by the Company from various counterparties was $65 million at September 30, 2021. The obligation to return such collateral is recorded in 	Accrued and
other current liabilities. Cash collateral advanced by the Company to counterparties was $36 million at December 31, 2020.
7. 	Inventories
Inventories consisted of:
($ in millions) 	September 30, 2021 	December 31, 2020
Finished goods 	$ 	1,628 	$ 	1,610
Raw materials and work in process 	6,135 	5,949
Supplies 	190 	146
Total (approximates current cost) 	7,953 	7,705
Increase (decrease) to LIFO cost 	23 	(81)
$ 	7,976 	$ 	7,624
Recognized as:
Inventories 	$ 	5,603 	$ 	5,554
Other assets 	2,373 	2,070
Amounts recognized as 	Other Assets 	are comprised almost entirely of raw materials and work in process inventories. At September 30, 2021 and
December 31, 2020, these amounts included $1.9 billion and $1.8 billion, respectively, of inventories not expected to be sold within one year. In addition, these
amounts included $519 million and $279 million at September 30, 2021 and December 31, 2020, respectively, of inventories produced in preparation for product
launches.
- 22 -

-- 22 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
8. 	Goodwill and Intangibles
In connection with the spin-off of Organon (see Note 2), goodwill was reduced by $1.4 billion. Additionally, other intangibles, on a net basis, were
reduced by $519 million, including products and products rights of $394 million and licenses of $125 million.
9. 	Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual
property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is
unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a
possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion
practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the
discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect
on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated.
These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall
accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported.
Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a
loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such
decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of
the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving 	Fosamax 	(Fosamax 	Litigation). As of September 30,
2021, approximately 3,470 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast
majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of 	Fosamax.
In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately
515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision
reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S.
Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the
judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s
opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether
the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and
the parties await the decision of the District Court.
Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. As part of the spin-off of Organon, Organon is required to
indemnify Merck for all liabilities relating to, arising from, or resulting from the 	Fosamax 	Litigation.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving 	Januvia 	and/or 	Janumet. As of September 30, 2021,
Merck is aware of approximately 730 product users alleging that 	Januvia 	and/or 	Janumet 	caused the development of pancreatic cancer and other injuries.
Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). On March 9, 2021,
the MDL Court issued an omnibus order granting defendants’ summary judgment motions based on preemption and failure to establish general causation, as well
as granting defendants’ motions to exclude
- 23 -

-- 23 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
plaintiffs’ expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and
on October 5, 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants.
Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles
(California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants’ summary judgment motions and also granting
defendants’ motions to exclude plaintiffs’ expert witnesses.
As of September 30, 2021, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017,
the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in
December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed
consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in 	Merck Sharp & Dohme Corp. v. Albrecht 	(relating to the
Fosamax 	matter discussed above). Merck filed the opinion in 	Albrecht 	with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided
in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued
a favorable decision concluding, consistent with 	Albrecht, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate
Court issued a mandate to the state trial court, which, as of September 30, 2021, had not scheduled a case management conference or otherwise taken action.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company
intends to continue defending against any remaining lawsuits.
Governmental Proceedings
As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from
various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as
Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition
and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other
similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries
or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those
proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia 	Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the
Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of 	Zetia 	alleging violations
of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a
federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’
motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and
recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying
in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and
in August 2019, retailer opt-out plaintiffs filed an amended complaint. In December 2019, the district court granted the Merck Defendants’ motion to dismiss to the
extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical)
and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class
certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers and,
in November 2020, the U.S. Court of Appeals for the Fourth Circuit granted the Merck Defendants’ motion for permission to appeal the district court’s order. In
August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In
September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification and briefing regarding that motion is pending.
In August 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary
judgment, and other motions. Those motions are now fully briefed, and the court has heard
- 24 -

-- 24 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
argument on certain of the motions. The court may hold additional hearings on the other motions. Trial in this matter has been adjourned.
Also in August 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser
class. The Merck Defendants objected to this report and recommendation. In August 2021, the district court overruled the Merck Defendants’ objections to the
report and recommendation and granted certification of a class of indirect purchasers. In September 2021, the Merck Defendants petitioned to appeal the class
certification decision to the Fourth Circuit. The Fourth Circuit denied that petition on September 30, 2021.
In September 2020, United Healthcare Services, Inc. filed a lawsuit in the U.S. District Court for the District of Minnesota against the Merck
Defendants and others (the UHC Action). The UHC Action makes similar allegations as those made in the 	Zetia 	class action. In September 2020, the U.S. Judicial
Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict 	Zetia 	litigation already in progress.
Defendants have filed a motion to dismiss.
In December 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others,
alleging defendants violated state antitrust laws in multiple states. Also, in December 2020, Centene Corporation and others filed a lawsuit in the Superior Court of
the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the
Zetia 	class action. In July 2021, the California Court ruled on defendants’ Motion to Quash for lack of personal jurisdiction, granting the motion as to the out-of-
state claims against defendants, and ordering limited jurisdictional discovery with regard to the California claims. In September 2021, the parties reached an
agreement that Humana and Centene would file their claims in New Jersey federal court, seek a transfer of those claims to the multidistrict 	Zetia 	litigation already
in progress, and subsequently dismiss the actions previously filed in California. The parties jointly sought a stay of the Superior Court action, pending filing of the
federal action. The Superior Court granted the stay on September 17, 2021.
Also, on July 16, 2021, Humana and Centene filed actions against the Merck Defendants in New Jersey in the Bergen County Superior Court, re-
asserting the claims that were dismissed in their California action. Those complaints have not yet been served, and Humana and Centene have agreed to dismiss
those actions once they have filed their complaints in New Jersey federal court.
In June 2021, Kaiser Foundation Health Plan, Inc. similarly filed a lawsuit in the Superior Court of the State of California, County of San Francisco,
against the same defendants as Humana and Centene. The Kaiser lawsuit alleges similar anticompetitive acts to those alleged in the 	Zetia 	class action. The Kaiser
action was removed to the U.S. District Court for the Northern District of California on July 16, 2021. In September 2021, the U.S. Judicial Panel on Multidistrict
Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict 	Zetia 	litigation already in progress.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market
generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file
patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company
intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of
such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for
these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.
Bridion 	— 	Between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act
notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of 	Bridion
(sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New
Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These
lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications
until June 2023 or until adverse court decisions, if any, whichever may occur earlier.
Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue
and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New
Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.
- 25 -

-- 25 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
The Company has settled with three generic companies providing that these generic companies can bring their generic versions of 	Bridion 	to the market
in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances.
Januvia, Janumet, Janumet XR 	— As previously disclosed, the FDA has granted pediatric exclusivity with respect to 	Januvia, 	Janumet, and Janumet
XR, which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to
the term of the key patent protection extends exclusivity on these products to January 2023. The Company anticipates that sales of 	Januvia 	and 	Janumet 	in the U.S.
will decline significantly after this loss of market exclusivity. However, 	Januvia, 	Janumet, and 	Janumet XR 	contain sitagliptin phosphate monohydrate and the
Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin (2027 salt/polymorph patent), which, if determined to be valid,
would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms until 2027 with the expiration of that patent, plus pediatric
exclusivity. In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of
invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware
against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of 	Januvia, 	Janumet, and 	Janumet XR 	following
expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the
Janumet 	formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the
Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S.
District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.
Prior to the beginning of the October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all
defendants scheduled to participate in that trial. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has
scheduled a five-day bench trial in December 2021.
In total, the Company has settled with 16 generic companies providing that these generic companies can bring their generic versions of 	Januvia 	and
Janumet 	to the market in May 2026 or earlier under certain circumstances, and their generic versions of 	Janumet XR 	to the market in July 2026 or earlier under
certain circumstances.
Additionally, in 2019, Mylan filed a petition for 	Inter Partes 	Review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of
some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the
challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were
not invalid. Mylan has appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit.
On March 1, 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide
DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). 	In that lawsuit, the Company alleged infringement of the 2027
salt/polymorph patent based on the filing of Zydus’s application seeking approval under 21 U.S.C. § 355(b)(2) of its sitagliptin tablets. 	The U.S. District Court for
the District of Delaware has set a three-day bench trial in this matter beginning on October 31, 2022.
In Germany, generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for 	Janumet. If the generic companies
are successful, 	Janumet 	could lose market exclusivity in Germany at the same time as the expiry of 	Januvia 	pediatric market exclusivity in September 2022. A
hearing was held in June 2021 and the court decided that the SPC for 	Janumet 	is invalid, which decision the Company has appealed. Challenges to the 	Janumet
SPC have also occurred in the following European countries: Austria, Czech Republic, Finland, France, Hungary, Italy, Portugal, Romania, Slovakia, and Sweden.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not
feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss
associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either
individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the
significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the
Company’s legal defense strategy and structure in light of the
- 26 -

-- 26 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information
regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of
September 30, 2021 and December 31, 2020 of approximately $225 million and $235 million, respectively, represents the Company’s best estimate of the
minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could
arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its
legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the
factors set forth, it believes it would be appropriate to do so.
10. 	Equity
Three Months Ended September 30,
Common Stock 	Other
Paid-In
Capital Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury Stock 	Non-
controlling
Interests 	Total	($ and shares in millions except per share amounts) 	Shares 	Par Value 	Shares 	Cost
Balance at July 1, 2020 	3,577 	$ 	1,788 	$ 	39,373 	$ 	49,724 	$ 	(6,393) 	1,048 	$ 	(56,850) 	$ 	102 	$ 	27,744
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	2,941 	— 	— 	— 	— 	2,941
Other comprehensive income, net of taxes 	— 	— 	— 	— 	10 	— 	— 	— 	10
Cash dividends declared on common stock ($0.61 per
share) 	— 	— 	— 	(1,558) 	— 	— 	— 	— 	(1,558)
Share-based compensation plans and other 	— 	— 	116 	— 	— 	(1) 	35 	— 	151
Net income attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	4 	4
Distributions attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(22) 	(22)
Balance at September 30, 2020 	3,577 	$ 	1,788 	$ 	39,489 	$ 	51,107 	$ 	(6,383) 	1,047 	$ 	(56,815) 	$ 	84 	$ 	29,270
Balance at July 1, 2021 	3,577 	$ 	1,788 	$ 	44,039 	$ 	48,777 	$ 	(4,628) 	1,044 	$ 	(56,682) 	$ 	94 	$ 	33,388
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	4,567 	— 	— 	— 	— 	4,567
Other comprehensive income, net of taxes 	— 	— 	— 	— 	38 	— 	— 	— 	38
Cash dividends declared on common stock ($0.65 per
share) 	— 	— 	— 	(1,653) 	— 	— 	— 	— 	(1,653)
Treasury stock shares purchased 	— 	— 	— 	— 	— 	8 	(583) 	— 	(583)
Share-based compensation plans and other 	— 	— 	110 	— 	— 	— 	21 	— 	131
Net income attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	4 	4
Distributions attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(29) 	(29)
Balance at September 30, 2021 	3,577 	1,788 	44,149 	51,691 	(4,590) 	1,052 	(57,244) 	69 	35,863
- 27 -

-- 27 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Nine Months Ended September 30,
Common Stock 	Other
Paid-In
Capital Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury Stock 	Non-
controlling
Interests 	Total	($ and shares in millions except per share amounts) 	Shares 	Par Value 	Shares 	Cost
Balance at January 1, 2020 	3,577 	$ 	1,788 	$ 	39,660 	$ 	46,602 	$ 	(6,193) 	1,038 	$ 	(55,950) 	$ 	94 	$ 	26,001
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	9,161 	— 	— 	— 	— 	9,161
Other comprehensive loss, net of taxes 	— 	— 	— 	— 	(190) 	— 	— 	— 	(190)
Cash dividends declared on common stock ($1.83 per
share) 	— 	— 	— 	(4,656) 	— 	— 	— 	— 	(4,656)
Treasury stock shares purchased 	— 	— 	— 	— 	— 	16 	(1,281) 	— 	(1,281)
Share-based compensation plans and other 	— 	— 	(171) 	— 	— 	(7) 	416 	— 	245
Net income attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	12 	12
Distributions attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(22) 	(22)
Balance at September 30, 2020 	3,577 	1,788 	39,489 	51,107 	(6,383) 	1,047 	(56,815) 	84 	29,270
Balance at January 1, 2021 	3,577 	$ 	1,788 	$ 	39,588 	$ 	47,362 	$ 	(6,634) 	1,047 	$ 	(56,787) 	$ 	87 	$ 	25,404
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	9,291 	— 	— 	— 	— 	9,291
Other comprehensive income, net of taxes 	— 	— 	— 	— 	1,595 	— 	— 	— 	1,595
Cash dividends declared on common stock ($1.95 per
share) 	— 	— 	— 	(4,962) 	— 	— 	— 	— 	(4,962)
Treasury stock shares purchased 	— 	— 	— 	— 	— 	11 	(822) 	— 	(822)
Spin-off of Organon & Co. 	— 	— 	4,643 	— 	449 	— 	— 	(1) 	5,091
Share-based compensation plans and other 	— 	— 	(82) 	— 	— 	(6) 	365 	— 	283
Net income attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	12 	12
Distributions attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(29) 	(29)
Balance at September 30, 2021 	3,577 	1,788 	44,149 	51,691 	(4,590) 	1,052 	(57,244) 	69 	35,863
11. 	Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic
benefit cost of such plans (including certain costs reported as part of discontinued operations) consisted of the following components:
Three Months Ended
September 30, Nine Months Ended
September 30,
2021 	2020 	2021 	2020
($ in millions) 	U.S. 	International 	U.S. 	International 	U.S. 	International 	U.S. 	International
Service cost 	$ 	104 	$ 	75 	$ 	96 	$ 	76 	$ 	302 	$ 	254 	$ 	270 	$ 	222
Interest cost 	102 	33 	107 	35 	305 	92 	323 	102
Expected return on plan assets 	(188) 	(105) 	(193) 	(104) 	(568) 	(313) 	(581) 	(309)
Amortization of unrecognized prior service
credit 	(9) 	(3) 	(12) 	(3) 	(29) 	(12) 	(37) 	(9)
Net loss amortization 	75 	32 	75 	32 	218 	110 	228 	94
Termination benefits 	2 	— 	1 	1 	54 	3 	5 	2
Curtailments 	(1) 	— 	1 	— 	15 	(27) 	4 	(1)
Settlements 	139 	— 	2 	— 	139 	2 	11 	2
$ 	224 	$ 	32 	$ 	77 	$ 	37 	$ 	436 	$ 	109 	$ 	223 	$ 	103
- 28 -

-- 28 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement
benefit plans. The net credit of such plans consisted of the following components:
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Service cost 	$ 	11 	$ 	13 	$ 	37 	$ 	39
Interest cost 	12 	14 	34 	43
Expected return on plan assets 	(20) 	(19) 	(59) 	(56)
Amortization of unrecognized prior service credit 	(16) 	(18) 	(48) 	(54)
Net gain amortization 	(12) 	(5) 	(30) 	(13)
Termination benefits 	— 	— 	37 	—
Curtailments 	(1) 	— 	(29) 	(1)
$ 	(26) 	$ 	(15) 	$ 	(58) 	$ 	(42)
Net periodic benefit cost (credit) for pension and other postretirement benefit plans in the first nine months of 2021 includes expenses for curtailments,
settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.
In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain
employees exiting Merck. Also, in connection with these restructuring actions, curtailments and settlements were recorded on pension plans. In addition, lump sum
payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of approximately $125 million in the third quarter and first nine
months of 2021. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. This remeasurement, which was calculated using
discount rates and asset values as of September 30, 2021, resulted in a net increase of $160 million to net pension liabilities and also resulted in a related
adjustment to 	AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in 	Other (income) expense, net 	(see Note 12),
with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in 	Restructuring costs 	if the event giving rise to the
termination benefits, curtailment or settlement is related to restructuring actions or in 	Income from Discontinued Operations, Net of Taxes and Amounts
Attributable to Noncontrolling Interests 	if related to the spin-off of Organon (each as noted above).
The transfer of employees to Organon in connection with the spin-off triggered remeasurements of some of the Company’s pension plans. These
remeasurements, which were calculated using discount rates and asset values as of the date of the spin-off, resulted in a $1.7 billion reduction to net pension
liabilities primarily due to higher discount rates. In addition, $99 million of net pension liabilities were transferred to Organon. The remeasurements and plan
transfers also resulted in a related adjustment to 	AOCL 	(see Note 15).
12. 	Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Interest income 	$ 	(7) 	$ 	(9) 	$ 	(27) 	$ 	(48)
Interest expense 	196 	203 	597 	624
Exchange losses 	46 	10 	202 	89
Income from investments in equity securities, net 	(683) 	(360) 	(1,535) 	(964)
Net periodic defined benefit plan cost (credit) other than service cost 	40 	(88) 	(159) 	(259)
Other, net 	(42) 	(68) 	(85) 	(79)
$ 	(450) 	$ 	(312) 	$ 	(1,007) 	$ 	(637)
Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and
losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. The
Company estimates that gains of approximately $540 million will be recorded in the fourth quarter of 2021 from ownership interests in investment funds.
Interest paid for the nine months ended September 30, 2021 and 2020 was $570 million and $605 million, respectively.
(1)
(1)
- 29 -

-- 29 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
13. 	Taxes on Income
The effective income tax rates from continuing operations were 13.2% and 14.0% for the third quarter of 2021 and 2020, respectively, and 14.4% and
15.1% for the first nine months of 2021 and 2020, respectively. The effective tax rates from continuing operations in the third quarter and first nine months of 2021
reflect the beneficial impact of the settlement of a foreign tax matter. The effective income tax rate from continuing operations for the first nine months of 2021
reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207 million related
to the settlement of certain federal income tax matters as discussed below.
In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a
result, the Company was required to make a payment of $190 million (of which $172 million related to Merck continuing operations and $18 million related to
Organon discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this
examination period and therefore the Company recorded a $236 million net tax benefit in the first nine months of 2021 (of which $207 million related to Merck
continuing operations and $29 million related to Organon discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits
and other related liabilities for tax positions relating to the years that were under examination.
14. 	Earnings Per Share
The calculations of earnings per share are as follows:
Three Months Ended
September 30, Nine Months Ended
September 30,
($ and shares in millions except per share amounts) 	2021 	2020 	2021 	2020
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 	$ 	4,567 	$ 	2,324 	$ 	8,525 	$ 	7,136
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling
Interests 	— 	617 	766 	2,025
Net Income Attributable to Merck & Co., Inc. 	$ 	4,567 	$ 	2,941 	$ 	9,291 	$ 	9,161
Average common shares outstanding 	2,530 	2,529 	2,531 	2,530
Common shares issuable 	6 	9 	8 	11
Average common shares outstanding assuming dilution 	2,536 	2,538 	2,539 	2,541
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	$ 	1.81 	$ 	0.92 	$ 	3.37 	$ 	2.82
Income from Discontinued Operations 	— 	0.24 	0.30 	0.80
Net Income 	$ 	1.81 	$ 	1.16 	$ 	3.67 	$ 	3.62
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common
Shareholders:
Income from Continuing Operations 	$ 	1.80 	$ 	0.92 	$ 	3.36 	$ 	2.81
Income from Discontinued Operations 	— 	0.24 	0.30 	0.80
Net Income 	$ 	1.80 	$ 	1.16 	$ 	3.66 	$ 	3.61
Issuable primarily under share-based compensation plans.
For the third quarter of 2021 and 2020, 8 million and 5 million, respectively, and for the first nine months of 2021 and 2020, 10 million and 5 million,
respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming
dilution because the effect would have been antidilutive.
(1)
(1)
- 30 -

-- 30 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
15. 	Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended September 30,
($ in millions) 	Derivatives 	Investments
Employee
Benefit
Plans
Foreign
Currency
Translation
Adjustment
Accumulated Other
Comprehensive
Income (Loss)
Balance July 1, 2020, net of taxes 	$ 	15 	$ 	— 	$ 	(4,162) 	$ 	(2,246) 	$ 	(6,393)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	(195) 	— 	2 	50 	(143)
Tax 	41 	— 	1 	35 	77
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	(154) 	— 	3 	85 	(66)
Reclassification adjustments, pretax 	22 	— 	72 	— 	94
Tax 	(5) 	— 	(13) 	— 	(18)
Reclassification adjustments, net of taxes 	17 	— 	59 	— 	76
Other comprehensive income (loss), net of taxes 	(137) 	— 	62 	85 	10
Balance September 30, 2020, net of taxes 	$ 	(122) 	$ 	— 	$ 	(4,100) 	$ 	(2,161) 	$ 	(6,383)
Balance July 1, 2021, net of taxes 	$ 	(26) 	$ 	— 	$ 	(3,028) 	$ 	(1,574) 	$ 	(4,628)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	72 	— 	(24) 	(96) 	(48)
Tax 	(16) 	— 	16 	12 	12
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	56 	— 	(8) 	(84) 	(36)
Reclassification adjustments, pretax 	36 	— 	68 	— 	104
Tax 	(8) 	— 	(22) 	— 	(30)
Reclassification adjustments, net of taxes 	28 	— 	46 	— 	74
Other comprehensive income (loss), net of taxes 	84 	— 	38 	(84) 	38
Balance September 30, 2021, net of taxes 	$ 	58 	$ 	— 	$ 	(2,990) 	$ 	(1,658) 	$ 	(4,590)
Nine Months Ended September 30,
($ in millions) 	Derivatives 	Investments
Employee
Benefit
Plans
Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2020, net of taxes 	$ 	31 	$ 	18 	$ 	(4,261) 	$ 	(1,981) 	$ 	(6,193)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	(126) 	3 	(19) 	(220) 	(362)
Tax 	27 	— 	12 	40 	79
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	(99) 	3 	(7) 	(180) 	(283)
Reclassification adjustments, pretax 	(68) 	(21) 	210 	— 	121
Tax 	14 	— 	(42) 	— 	(28)
Reclassification adjustments, net of taxes 	(54) 	(21) 	168 	— 	93
Other comprehensive income (loss), net of taxes 	(153) 	(18) 	161 	(180) 	(190)
Balance September 30, 2020, net of taxes 	$ 	(122) 	$ 	— 	$ 	(4,100) 	$ 	(2,161) 	$ 	(6,383)
Balance January 1, 2021, net of taxes 	$ 	(266) 	$ 	— 	$ 	(4,540) 	$ 	(1,828) 	$ 	(6,634)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	193 	— 	1,739 	(167) 	1,765
Tax 	(41) 	— 	(385) 	(84) 	(510)
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	152 	— 	1,354 	(251) 	1,255
Reclassification adjustments, pretax 	218 	— 	210 	— 	428
Tax 	(46) 	— 	(42) 	— 	(88)
Reclassification adjustments, net of taxes 	172 	— 	168 	— 	340
Other comprehensive income (loss), net of taxes 	324 	— 	1,522 	(251) 	1,595
Spin-off of Organon (see Note 2) 	— 	— 	28 	421 	449
Balance September 30, 2021, net of taxes 	$ 	58 	$ 	— 	$ 	(2,990) 	$ 	(1,658) 	$ 	(4,590)
Primarily relates to foreign currency cash flow hedges that were reclassified from 	AOCL 	to 	Sales.
Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from 	AOCL 	to 	Other (income) expense, net.
Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 11).
(1) 	(3)
(1) 	(3)
(1) 	(2) 	(3)
(1) 	(3)
(1)
(2)
(3)
- 31 -

-- 31 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
16. 	Segment Reporting
The Company’s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal
Health segments, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic
and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products
primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy
benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at
physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large
component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is
funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as
health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company
also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians,
distributors and animal producers.
The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical
services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.
- 32 -

-- 32 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Sales of the Company’s products were as follows:
Three Months Ended September 30, 	Nine Months Ended September 30,
2021 	2020 	2021 	2020
($ in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Pharmaceutical:
Oncology
Keytruda 	$ 	2,580 	$ 	1,954 	$ 	4,534 	$ 	2,157 	$ 	1,559 	$ 	3,715 	$ 	7,108 	$ 	5,501 	$ 	12,609 	$ 	6,106 	$ 	4,281 	$ 	10,387
Alliance revenue - Lynparza 	129 	117 	246 	107 	89 	196 	371 	350 	721 	297 	223 	519
Alliance revenue - Lenvima 	114 	74 	188 	82 	60 	142 	287 	211 	498 	270 	152 	421
Vaccines
Gardasil/Gardasil 	9 	839 	1,154 	1,993 	579 	608 	1,187 	1,605 	2,539 	4,144 	1,209 	1,732 	2,941
ProQuad/M-M-R 	II/Varivax 	537 	125 	661 	437 	139 	576 	1,255 	371 	1,626 	1,033 	356 	1,390
Pneumovax 	23 	181 	97 	277 	276 	99 	375 	354 	247 	600 	478 	270 	748
RotaTeq 	135 	92 	227 	114 	96 	210 	364 	229 	593 	355 	246 	601
Vaqta 	32 	16 	48 	32 	19 	51 	80 	58 	138 	79 	60 	139
Hospital Acute Care
Bridion 	181 	188 	369 	162 	157 	320 	545 	551 	1,096 	412 	431 	843
Prevymis 	39 	57 	96 	32 	46 	77 	111 	159 	270 	87 	113 	200
Noxafil 	19 	45 	64 	13 	66 	79 	48 	149 	197 	27 	220 	247
Primaxin 	— 	69 	70 	1 	73 	74 	— 	194 	194 	2 	187 	189
Cancidas 	1 	56 	56 	1 	49 	50 	4 	164 	168 	2 	147 	148
Invanz 	(2) 	55 	53 	1 	50 	51 	(2) 	159 	157 	7 	152 	159
Zerbaxa 	(1) 	(1) 	(2) 	20 	23 	43 	(5) 	(6) 	(11) 	57 	54 	112
Immunology
Simponi 	— 	203 	203 	— 	209 	209 	— 	619 	619 	— 	615 	615
Remicade 	— 	73 	73 	— 	82 	82 	— 	233 	233 	— 	242 	242
Neuroscience
Belsomra 	23 	58 	81 	18 	63 	81 	56 	183 	238 	67 	177 	244
Virology
Isentress/Isentress 	HD 	77 	112 	189 	92 	113 	205 	222 	368 	590 	243 	403 	646
Cardiovascular
Alliance revenue-Adempas/Verquvo 	73 	27 	100 	78 	5 	83 	222 	26 	248 	200 	16 	216
Adempas 	— 	59 	59 	— 	55 	55 	— 	188 	188 	— 	167 	167
Diabetes
Januvia 	365 	487 	852 	342 	479 	821 	997 	1,448 	2,445 	1,110 	1,339 	2,449
Janumet 	86 	401 	487 	105 	400 	506 	244 	1,205 	1,449 	361 	1,138 	1,499
Other pharmaceutical 	262 	308 	572 	193 	333 	526 	745 	957 	1,704 	706 	969 	1,675
Total Pharmaceutical segment sales 	5,670 	5,826 	11,496 	4,842 	4,872 	9,714 	14,611 	16,103 	30,714 	13,108 	13,690 	26,797
Animal Health:
Livestock 	190 	675 	864 	165 	593 	758 	508 	1,996 	2,503 	448 	1,697 	2,145
Companion Animals 	277 	276 	553 	234 	228 	462 	855 	948 	1,804 	676 	714 	1,390
Total Animal Health segment sales 	467 	951 	1,417 	399 	821 	1,220 	1,363 	2,944 	4,307 	1,124 	2,411 	3,535
Other segment sales 	— 	— 	— 	— 	— 	— 	— 	— 	— 	23 	— 	23
Total segment sales 	6,137 	6,777 	12,913 	5,241 	5,693 	10,934 	15,974 	19,047 	35,021 	14,255 	16,101 	30,355
Other 	139 	101 	241 	9 	(14) 	(5) 	192 	(30) 	162 	46 	168 	215
$ 	6,276 	$ 	6,878 	$ 	13,154 	$ 	5,250 	$ 	5,679 	$ 	10,929 	$ 	16,166 	$ 	19,017 	$ 	35,183 	$ 	14,301 	$ 	16,269 	$ 	30,570
U.S. plus international may not equal total due to rounding.
Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).
Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).
Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested in the first quarter of 2020.
Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. Other for the three and nine months
ended September 30, 2021 also includes $135 million and $185 million, respectively, related to the achievement of milestones for an out-licensed product that triggered contingent payments
to Merck.
(1)
(1)
(2)
(3)
(4)
(5)
(1)
(2)
(3)
(4)
(5)
- 33 -

-- 33 of 59 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted
customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements
with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan
participant. These discounts, in the aggregate, reduced U.S. sales by $3.1 billion and $2.9 billion for the three months ended September 30, 2021 and 2020,
respectively, and $9.1 billion and $8.3 billion for the nine months ended September 30, 2021 and 2020, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
United States 	$ 	6,276 	$ 	5,250 	$ 	16,166 	$ 	14,301
Europe, Middle East and Africa 	3,342 	2,946 	9,912 	8,537
China 	1,307 	791 	3,004 	2,060
Japan 	638 	671 	1,929 	1,875
Asia Pacific (other than China and Japan) 	613 	545 	1,782 	1,560
Latin America 	599 	499 	1,631 	1,374
Other 	379 	227 	759 	863
$ 	13,154 	$ 	10,929 	$ 	35,183 	$ 	30,570
A reconciliation of segment profits to 	Income from Continuing Operations Before Taxes 	is as follows:
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Segment profits:
Pharmaceutical segment 	$ 	8,606 	$ 	7,026 	$ 	22,450 	$ 	19,235
Animal Health segment 	505 	459 	1,629 	1,347
Other segment 	— 	(1) 	— 	1
Total segment profits 	9,111 	7,484 	24,079 	20,583
Other profits 	141 	(28) 	29 	135
Unallocated:
Interest income 	7 	9 	27 	48
Interest expense 	(196) 	(203) 	(597) 	(624)
Amortization 	(360) 	(406) 	(1,231) 	(1,393)
Depreciation 	(358) 	(367) 	(1,031) 	(1,105)
Research and development 	(2,312) 	(3,231) 	(8,775) 	(7,251)
Restructuring costs 	(107) 	(113) 	(487) 	(265)
Other unallocated, net 	(660) 	(439) 	(2,044) 	(1,720)
$ 	5,266 	$ 	2,706 	$ 	9,970 	$ 	8,408
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly
incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative
expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker,
Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck
Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses,
nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed
assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the
amortization of intangible assets and purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains
or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other
miscellaneous income or expense items.
- 34 -

-- 34 of 59 --

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The
distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the
transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands
franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the women’s health,
biosimilars and established brands businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s
consolidated financial statements through the date of the spin-off (see Note 2 to the condensed consolidated financial statements).
Other Developments
Business Developments
Below is a summary of significant business development activity thus far in 2021. See Note 3 to the condensed consolidated financial statements for
additional information.
In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover,
develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three
different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including
regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in 	Research and
development 	expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront
payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is
eligible to receive future contingent milestone payments and tiered royalties on future sales.
In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in
HIV that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead’s investigational capsid inhibitor,
lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with
other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.
In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to
address the unmet needs of patients living with autoimmune diseases, for total consideration of $1.9 billion. Pandion is advancing a pipeline of precision immune
modulators targeting critical immune control nodes.
In September 2021, Merck and Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, entered into a definitive agreement
under which Merck will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. Acceleron is focused on harnessing the
power of the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and
repair. Under the terms of the acquisition agreement, Merck, through a subsidiary, initiated a tender offer to acquire all outstanding shares of Acceleron. The
closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the total number of Acceleron’s
outstanding shares, receipt of applicable regulatory approvals, and other customary conditions. The transaction is expected to close in the fourth quarter of 2021.
Coronavirus Disease 2019 (COVID-19) Update
Overall, in response to the COVID-19 pandemic, Merck is focused on protecting the safety of its employees, ensuring that its supply of medicines and
vaccines reaches its patients, contributing its scientific expertise to the development of an antiviral therapy, supporting efforts to expand manufacturing capacity
and supply of SARS-CoV-2/COVID-19 medicines and vaccines (see below), and supporting health care providers and Merck’s communities. Although COVID-
19-related disruptions negatively affected results for the third quarter and first nine months of 2021, Merck continues to experience strong global underlying
demand across its business.
In the third quarter and first nine months of 2021, the estimated negative impact of the COVID-19 pandemic to Merck’s sales was approximately $350
million and $1.3 billion, respectively, all of which related to the Pharmaceutical segment. In the third quarter and first nine months of 2020, the estimated negative
impact of the COVID-19 pandemic to Merck’s Pharmaceutical sales was approximately $400 million and $1.7 billion, respectively. Roughly 75% of Merck’s
- 35 -

-- 35 of 59 --

Pharmaceutical segment revenue is comprised of physician-administered products, which, despite strong underlying demand, have been affected by social
distancing measures and fewer well visits.
In April 2021, Merck announced it was discontinuing the development of MK-7110 (formerly known as CD24Fc) for the treatment of hospitalized
patients with COVID-19 (see Note 3 to the condensed consolidated financial statements). This decision resulted in charges of $207 million to 	Cost of sales 	in the
first nine months of 2021.
Operating expenses reflect a minor positive effect in the third quarter and first nine months of 2021 as investments in COVID-19-related research
programs largely offset the favorable impact of lower spending in other areas due to the COVID-19 pandemic. Operating expenses were positively affected in the
third quarter and first nine months of 2020 by approximately $100 million and $500 million, respectively, primarily driven by lower promotional and selling costs,
as well as lower research and development expenses due to the COVID-19 pandemic.
Merck continues to believe that global health systems and patients have largely adapted to the impacts of the COVID-19 pandemic, and that while
certain negative impacts will persist, the trend will continue to improve. For the full year of 2021, Merck assumes a net unfavorable impact to sales of less than 3%
due to the COVID-19 pandemic, all of which relates to the Pharmaceutical segment.
In November 2021, the Medicines and Healthcare products Regulatory Agency in the United Kingdom (U.K.) granted authorization for molnupiravir
(MK-4482, EIDD-2801), an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2
diagnostic test and who have at least one risk factor for developing severe illness. The authorization is based on positive results from a planned interim analysis
from the Phase 3 MOVe-OUT clinical trial, which evaluated molnupiravir in non-hospitalized, unvaccinated adult patients with laboratory-confirmed mild-to-
moderate COVID-19, symptom onset within five days of study randomization and at least one risk factor associated with poor disease outcomes. In the U.K.,
Lagevrio 	is the planned trademark for molnupiravir. In October 2021, Merck submitted an Emergency Use Authorization (EUA) application to the U.S. Food and
Drug Administration (FDA) for molnupiravir for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19
and/or hospitalization. The FDA subsequently announced a November 30, 2021 meeting of its Antimicrobial Drugs Advisory Committee to discuss the available
data supporting the use of molnupiravir to treat mild-to-moderate COVID-19 in adults who have tested positive for COVID-19 and who are at high risk of
progression to severe COVID-19, including hospitalization or death. Also in October 2021, the European Medicines Agency (EMA) initiated a rolling review for
molnupiravir. Merck plans to work with the Committee for Medicinal Products for Human Use (CHMP) of the EMA to complete the rolling review process to
facilitate 	initiating 	the formal review of the Marketing Authorization 	Application. Merck is developing molnupiravir in collaboration 	with Ridgeback
Biotherapeutics LP (Ridgeback Bio). The companies are actively working with other regulatory agencies worldwide to submit applications for emergency use or
marketing authorization in the coming months. In anticipation of the results from the MOVe-OUT trial and the potential for regulatory authorization or approval,
Merck has been producing molnupiravir at risk. Merck expects to produce 10 million courses of treatment by the end of 2021, with at least 20 million additional
courses expected to be produced in 2022. In June 2021, Merck announced a procurement agreement with the U.S. government under which Merck will supply
approximately 1.7 million courses of molnupiravir to the U.S. government upon EUA or approval from the FDA, which will be delivered in scheduled increments.
This procurement of molnupiravir will be supported in whole or in part with federal funds. Additionally, Merck has entered into supply and advance purchase
commitments for molnupiravir with other governments worldwide, including Australia, South Korea and New Zealand pending regulatory authorization, as well as
the U.K., and is currently in discussions with other governments. If approved, Merck will be the principal on sales transactions, recognizing sales and related costs,
with profit sharing amounts recorded within 	Cost of sales. Profits from the collaboration will be split equally between the partners.
Merck is committed to providing timely access to molnupiravir globally, if it is authorized or approved, and intends to implement a tiered pricing
approach based on World Bank country income criteria to reflect countries’ relative ability to finance their health response to the pandemic. As part of its
commitment to widespread global access, Merck has entered into non-exclusive voluntary licensing agreements for molnupiravir with established Indian generic
manufacturers. Merck and the Medicines Patent Pool (MPP) also signed a voluntary licensing agreement to facilitate affordable global access for molnupiravir.
Under the terms of the agreement, the MPP will be permitted to further license non-exclusive sublicenses to manufacturers and diversify the manufacturing base
for the supply of quality-assured or WHO-prequalified molnupiravir to countries covered by the MPP license, subject to local regulatory authorization. Merck,
Ridgeback Bio and Emory University will not receive royalties for sales of molnupiravir under this agreement (molnupiravir was invented at Emory University and
licensed to Ridgeback Bio) for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
These agreements will help expand access to molnupiravir in more than 100 low- and middle-income countries.
In March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-
CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant
Secretary for Preparedness and Response
- 36 -

-- 36 of 59 --

within the U.S. Department of Health and Human Services, will provide Merck with funding to adapt and make available a number of existing manufacturing
facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. Merck has also entered into agreements to support the manufacturing and supply
of Johnson & Johnson’s SARS-CoV-2/COVID-19 vaccine. Merck will use its facilities in the U.S. to produce drug substance, formulate and fill vials of Johnson &
Johnson’s vaccine.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S.
health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private
sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and
patented drugs. In addition, the Company’s sales performance in the first nine months of 2021 was negatively affected by other cost-reduction measures taken by
governments and other third parties to lower health care costs. In the U.S., the Biden Administration and Congress continue to discuss legislation designed to
control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively
affect sales performance.
Operating Results
Sales
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
United States 	$ 	6,276 	$ 	5,250 	20 	% 	20 	% 	$ 	16,166 	$ 	14,301 	13 	% 	13 	%
International 	6,878 	5,679 	21 	% 	18 	% 	19,017 	16,269 	17 	% 	13 	%
Total 	$ 	13,154 	$ 	10,929 	20 	% 	19 	% 	$ 	35,183 	$ 	30,570 	15 	% 	13 	%
U.S. plus international may not equal total due to rounding.
Worldwide sales grew 20% to $13.2 billion in the third quarter of 2021 and rose 15% to $35.2 billion in the first nine months of 2021. Revenue
performance in both periods primarily reflects higher sales in the oncology franchise largely driven by strong growth of 	Keytruda 	(pembrolizumab) and increased
alliance revenue from Lynparza (olaparib) and Lenvima (lenvatinib), as well as higher sales in the vaccines franchise, primarily attributable to growth in 	Gardasil
(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/Gardasil 	9 (Human Papillomavirus 9-valent Vaccine, Recombinant),
Varivax 	(Varicella Virus Vaccine Live) and 	ProQuad 	(Measles, Mumps, Rubella and Varicella Virus Vaccine Live). Higher sales of certain hospital acute care
products, including 	Bridion 	(sugammadex) Injection and 	Prevymis 	(letermovir), as well as higher sales of Animal Health products also drove revenue growth in the
third quarter and first nine months of 2021. Additionally, sales in the third quarter and first nine months of 2021 also benefited from the achievement of milestones
for an out-licensed product that triggered contingent payments to Merck. As discussed above, the COVID-19 pandemic unfavorably affected sales in the third
quarter and first nine months of 2021, but to a lesser extent than in the comparable periods of 2020 which benefited year-over-year sales growth.
Revenue growth in both periods was partially offset by lower sales of 	Pneumovax 	23 (pneumococcal vaccine polyvalent) and the suspension of sales of
hospital acute care product 	Zerbaxa 	(ceftolozane and tazobactam) for injection. Lower sales of diabetes product 	Janumet 	(sitagliptin/metformin HCl) also partially
offset revenue growth in the first nine months of 2021.
See Note 16 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select
products in the franchises follows.
- 37 -

-- 37 of 59 --

Pharmaceutical Segment
Oncology
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Keytruda 	$ 	4,534 	$ 	3,715 	22 	% 	21 	% 	$ 	12,609 	$ 	10,387 	21 	% 	19 	%
Alliance Revenue - Lynparza 	246 	196 	25 	% 	25 	% 	721 	519 	39 	% 	35 	%
Alliance Revenue 	- 	Lenvima 	188 	142 	32 	% 	30 	% 	498 	421 	18 	% 	15 	%
Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4 to the condensed consolidated financial statements).
Keytruda 	is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with
cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal cancer, gastric or gastroesophageal junction
adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel
cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer including MSI-H/dMMR colorectal cancer, primary
mediastinal large B-cell lymphoma, tumor mutational burden-high (TMB-H) solid tumors, and urothelial carcinoma including non-muscle invasive bladder cancer.
Keytruda 	is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in
combination with chemotherapy for esophageal cancer, in combination with chemotherapy for gastric cancer, in combination with chemotherapy for HNSCC, in
combination with chemotherapy for triple-negative-breast cancer (TNBC), in combination with axitinib for renal cell carcinoma (RCC), and in combination with
Lenvima for both endometrial carcinoma and RCC. The 	Keytruda 	clinical development program includes studies across a broad range of cancer types. See
“Research and Development Update” below.
Global sales of 	Keytruda 	grew 22% and 21% in the third quarter and first nine months of 2021, respectively. Sales growth in both periods was driven by
higher demand as the Company continues to launch 	Keytruda 	with multiple new indications globally, although the COVID-19 pandemic had a dampening effect on
growing demand negatively affecting the number of new patients starting treatment. Sales in the U.S. continue to build across the multiple approved indications, in
particular for the treatment of advanced NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous and squamous metastatic NSCLC,
along with uptake in the RCC, TNBC, MSI-H cancer, esophageal cancer and HNSCC indications. 	Keytruda 	sales growth in international markets was driven by
continued uptake predominately for the NSCLC, HNSCC and RCC indications, particularly in Europe. Sales growth in the third quarter and first nine months of
2021 was partially offset by lower pricing in Europe, China and Japan.
In March 2021, the FDA approved 	Keytruda 	for the treatment of certain patients with locally advanced or metastatic esophageal or gastroesophageal
junction carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with chemotherapy. The approval was based on the
results of the KEYNOTE-590 trial.
In May 2021, the FDA approved 	Keytruda 	in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable
or metastatic human epidermal growth factor receptor 2 (HER2) positive gastric or gastroesophageal junction adenocarcinoma based on the results of the
KEYNOTE-811 trial. This indication is approved under accelerated approval based on tumor response rate and durability of response; continued approval for this
indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
In July 2021, the FDA approved 	Keytruda 	for the treatment of patients with high-risk, early-stage TNBC in combination with chemotherapy as
neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery, based on the KEYNOTE-522 trial. Additionally, the FDA converted
the accelerated approval of 	Keytruda 	in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose
tumors express PD-L1 that was originally granted in 2020 to a full (regular) approval based on confirmatory data from KEYNOTE-522.
Also in July 2021, the FDA approved 	Keytruda 	as monotherapy for the treatment of patients with locally advanced cSCC that is not curable by surgery
or radiation based on data from the KEYNOTE-629 trial.
Additionally, in July 2021, the FDA approved the combination of 	Keytruda 	plus Lenvima for the treatment of patients with advanced endometrial
carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or
radiation. The approval for this population is based on results from the KEYNOTE-775/Study 309 trial, which was the confirmatory trial for the accelerated
approval by the FDA in 2019.
In August 2021, Merck announced a label update for 	Keytruda 	for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S.
The FDA has converted this indication from an accelerated to a full (regular) approval.
(1)
(1)
(1)
- 38 -

-- 38 of 59 --

In addition, as part of the label update, this indication has been revised to be for the treatment of patients with locally advanced or metastatic urothelial carcinoma
who are not eligible for any platinum-containing chemotherapy.
Also in August 2021, the FDA approved the combination of 	Keytruda 	and Lenvima for the first-line treatment of adult patients with advanced RCC
based on results from the KEYNOTE-581 trial/Study 307 trial.
In October 2021, the FDA approved 	Keytruda 	in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with
persistent, recurrent or metastatic cervical cancer based on the KEYNOTE-826 trial. Additionally, the FDA converted the accelerated approval of 	Keytruda 	as a
single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy to a regular approval based
on confirmatory data from KEYNOTE-826. This approval was originally granted in June 2018 based on results from the KEYNOTE-158 trial.
In March 2021, Merck announced it was voluntarily withdrawing the U.S. indication for 	Keytruda 	for the treatment of patients with metastatic SCLC
with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The withdrawal of this indication was done in
consultation with the FDA and does not affect other indications for 	Keytruda. Accelerated approval for this indication was granted in 2019 and was contingent
upon completion of the post-marketing requirement establishing superiority of 	Keytruda 	as determined by overall survival (OS). As announced in January 2020,
KEYNOTE-604, the confirmatory Phase 3 trial for this indication, met one of its dual primary endpoints of progression-free survival (PFS) but did not reach
statistical significance for the other primary endpoint of OS.
In July 2021, Merck announced that it plans to voluntarily withdraw the U.S. accelerated approval indication for 	Keytruda 	for the treatment of patients
with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1, with disease progression on or
after two or more prior lines of therapy. The decision was made in consultation with the FDA following the Oncologic Drugs Advisory Committee evaluation of
this third-line gastric cancer indication for 	Keytruda 	as a monotherapy because it failed to meet its post-marketing requirement of demonstrating an OS benefit in a
Phase 3 study. The withdrawal of this indication was done in consultation with the FDA and does not affect other indications for 	Keytruda. As agreed with the
FDA, Merck will initiate the withdrawal in January 2022.
In January 2021, 	Keytruda 	was approved by the European Commission (EC) as a first-line treatment in adult patients with MSI-H or dMMR colorectal
cancer based on the results of the KEYNOTE-177 study.
In March 2021, the EC approved an expanded label for 	Keytruda 	as monotherapy for the treatment of adult and pediatric patients aged 3 years and older
with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment
option. This approval is based on results from the KEYNOTE-204 and KEYNOTE-087 trials. This is the first pediatric approval for 	Keytruda 	in the European
Union (EU).
In May 2021, the EC approved the addition of the 400 mg every six weeks (Q6W) dosing regimen to indications where 	Keytruda 	is administered in
combination with other anticancer agents.
Also in May 2021, the EC approved an update to the European label for 	Keytruda 	to include data from KEYNOTE-361. In the EU, 	Keytruda 	is
approved for the treatment of adult patients with advanced or metastatic urothelial carcinoma (bladder cancer) who are not eligible for cisplatin-containing
chemotherapy and whose tumors express PD-L1. This approval was based on KEYNOTE-052; KEYNOTE-361 was conducted as part of a post-marketing
commitment following the initial approval of 	Keytruda 	for these patients.
In June 2021, the EC approved 	Keytruda 	in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or
metastatic carcinoma of the esophagus or HER2-negative gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1. This approval was
based on results from the KEYNOTE-590 trial.
In October 2021, the EC approved 	Keytruda 	in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or
metastatic TNBC in adults whose tumors express PD-L1 and who have not received prior chemotherapy for metastatic disease based on the KEYNOTE-355 trial.
In August 2021, 	Keytruda 	received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency: for the treatment of patients with
PD-L1-positive, hormone receptor-negative and HER2-negative, inoperable or recurrent breast cancer, based on the results of the KEYNOTE-355 trial; and as a
monotherapy for the treatment of patients with unresectable, advanced or recurrent MSI-H colorectal cancer, based on results of the KEYNOTE-177 trial.
In June 2021, 	Keytruda 	was approved by the China National Medical Products Administration (NMPA) as a first-line treatment in adult patients with
MSI-H or dMMR colorectal cancer that is KRAS, NRAS and BRAF (all wild-type) based on the results of the KEYNOTE-177 study. In September 2021,
Keytruda 	was approved by the China NMPA in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or
metastatic carcinoma of the esophagus or gastroesophageal junction based on the KEYNOTE-590 trial.
- 39 -

-- 39 of 59 --

Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca)
(see Note 4 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced ovarian, breast, pancreatic and
prostate cancers. Alliance revenue related to Lynparza increased 25% and 39% in the third quarter and first nine months of 2021, respectively. Sales growth in both
periods was largely driven by continued uptake across the multiple approved indications in the U.S. and Europe. Higher demand in China also contributed to sales
growth in the year-to-date period. In June 2021, Lynparza was granted conditional approval in China as monotherapy for the treatment of certain previously treated
adult patients with germline or somatic 	BRCA-mutated metastatic castration-resistant prostate cancer based on the results of the PROfound trial.
Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 4 to the condensed
consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for
certain patients with RCC, in combination with 	Keytruda 	for the treatment of certain patients with endometrial carcinoma, and in combination with 	Keytruda 	for
the treatment of certain patients with RCC. Alliance revenue related to Lenvima grew 32% and 18% in the third quarter and first nine months of 2021, respectively.
Sales growth in both periods reflects higher demand in China and the U.S.
In June 2021, Koselugo (selumetinib) was granted conditional approval in the EU for the treatment of pediatric patients three years of age and older
with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on positive results from the National Cancer Institute Cancer
Therapy Evaluation Program-sponsored SPRINT Stratum 1 trial. Koselugo was approved by the FDA in April 2020. Koselugo is part of the same collaboration
with AstraZeneca referenced above that includes Lynparza.
In August 2021, the FDA approved 	Welireg 	(belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients
with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors,
not requiring immediate surgery. The approval was based on results from the open-label Study 004 trial. 	Welireg 	was obtained as part of Merck’s 2019 acquisition
of Peloton Therapeutics, Inc. (Peloton). Pursuant to the acquisition agreement, Merck made a $50 million capitalized milestone payment to former Peloton
shareholders upon first commercial sale of 	Welireg 	in the U.S.
Vaccines
Three Months Ended
September 30,
% Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Gardasil/Gardasil 	9 	$ 	1,993 	$ 	1,187 	68 	% 	63 	% 	$ 	4,144 	$ 	2,941 	41 	% 	35 	%
ProQuad 	244 	218 	12 	% 	12 	% 	598 	507 	18 	% 	17 	%
M-M-R 	II 	127 	115 	11 	% 	10 	% 	295 	287 	3 	% 	2 	%
Varivax 	290 	243 	19 	% 	19 	% 	733 	595 	23 	% 	23 	%
Pneumovax 	23 	277 	375 	(26)% 	(26) 	% 	600 	748 	(20)% 	(21) 	%
RotaTeq 	227 	210 	8 	% 	7 	% 	593 	601 	(1)% 	(3) 	%
Worldwide sales of 	Gardasil/Gardasil 	9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus
(HPV), grew 68% and 41% in the third quarter and first nine months of 2021, respectively. Sales growth in both periods was driven primarily by strong global
demand, particularly in China which also benefited from increased supply, and in the U.S. which also benefited from the timing of public sector purchases. Higher
pricing in China and the U.S. also contributed to sales growth in both periods.
Global sales of 	ProQuad, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, grew 12% and 18% in the third
quarter and first nine months of 2021, respectively, primarily due to higher sales in the U.S. reflecting higher demand driven by the ongoing COVID-19 pandemic
recovery, as well as higher pricing.
Worldwide sales of 	M‑M‑R 	II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, grew
11% and 3% in the third quarter and first nine months of 2021, respectively, primarily due to higher sales in the U.S. reflecting the ongoing COVID-19 pandemic
recovery inclusive of higher public sector mix of business. Lower demand and lower government tenders in international markets partially offset 	M‑M‑R 	II sales
growth in both periods.
Global sales of 	Varivax, a vaccine to help prevent chickenpox (varicella), grew 19% and 23% in the third quarter and first nine months of 2021,
respectively, primarily reflecting the ongoing COVID-19 pandemic recovery and higher pricing in the U.S. Higher government tenders in Brazil also contributed to
Varivax 	sales growth for the first nine months of 2021.
- 40 -

-- 40 of 59 --

Worldwide sales of 	Pneumovax 	23, a vaccine to help prevent pneumococcal disease, declined 26% and 20% in the third quarter and first nine months of
2021, respectively, primarily driven by lower demand in the U.S. reflecting prioritization of COVID-19 vaccination.
Global sales of 	RotaTeq 	(Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children,
grew 8% in the third quarter of 2021 largely attributable to higher public sector purchases in the U.S., partially offset by lower demand in certain international
markets. Worldwide sales of 	RotaTeq 	declined 1% in the first nine months of 2021 reflecting lower demand in certain international markets, partially offset by
higher public sector purchases in the U.S.
In July 2021, the FDA approved 	Vaxneuvance 	(Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive
disease caused by 15 	Streptococcus pneumoniae 	serotypes in adults 18 years of age and older. The approval was based on data from seven clinical studies assessing
safety, tolerability, and immunogenicity in adults. In October 2021, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on
Immunization Practices (ACIP) voted to provisionally recommend vaccination either with a sequential regimen of 	Vaxneuvance 	followed by 	Pneumovax 	23, or
with a single dose of 20-valent pneumococcal conjugate vaccine both for adults 65 years and older and for adults ages 19 to 64 with certain underlying medical
conditions. These provisional recommendations will be reviewed by the director of the CDC and the U.S. Department of Health and Human Services, and final
recommendations will become official when published in the CDC’s 	Morbidity and Mortality Weekly Report. In September 2021, Merck announced a settlement
and license agreement with Pfizer Inc., (Pfizer) resolving all worldwide patent infringement litigation related to the use of Merck’s investigational and licensed
pneumococcal conjugate vaccine (PCV) products, including 	Vaxneuvance. Under the terms of the agreement, Merck will make certain regulatory milestone
payments to Pfizer, as well as royalty payments on the worldwide sales of its PCV products. The Company will pay royalties of 7.25% of net sales of all Merck
PCV products through 2026; and 2.5% of net sales of all Merck PCV products from 2027 through 2035.
Vaxelis 	(Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine),
developed as part of a U.S.-based partnership between Merck and Sanofi Pasteur, is now available in the U.S. for active immunization of children six weeks
through four years of age to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to 	Haemophilus influenzae 	type b. In
February 2021, the CDC’s ACIP included 	Vaxelis 	as a combination vaccine option in the CDC’s Recommended Child and Adolescent Immunization Schedule.
Sales of 	Vaxelis 	in the U.S. are made through the U.S.-based Merck/Sanofi Pasteur partnership, the results of which are reflected in equity income from affiliates
included in 	Other (income) expense, net. 	Supply sales to the partnership are recorded within 	Sales. 	Vaxelis 	is also approved in the EU where it is marketed directly
by Merck and Sanofi Pasteur.
Hospital Acute Care
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Bridion 	$ 	369 	$ 	320 	16 	% 	15 	% 	$ 	1,096 	$ 	843 	30 	% 	27 	%
Prevymis 	96 	77 	23 	% 	22 	% 	270 	200 	35 	% 	31 	%
Noxafil 	64 	79 	(19)% 	(20) 	% 	197 	247 	(20)% 	(23) 	%
Zerbaxa 	(2) 	43 	(105)% 	(105) 	% 	(11) 	112 	(110)% 	(110) 	%
Worldwide sales of 	Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 16% and 30% in the third quarter
and first nine months of 2021, respectively, due to higher demand globally, particularly in the U.S. and Europe, attributable in part to the COVID-19 pandemic
recovery. 	Bridion 	was also approved by the FDA in June 2021 for pediatric patients aged 2 years and older undergoing surgery.
Worldwide sales of 	Prevymis, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive
recipients of an allogenic hematopoietic stem cell transplant, grew 23% and 35% in the third quarter and first nine months of 2021, respectively, due to continued
uptake since launch in several international markets, particularly in Europe and the U.S. 	Prevymis 	was approved by the EC in January 2018 and by the FDA in
November 2017.
Global sales of 	Noxafil 	(posaconazole), an antifungal agent for the prevention of certain invasive fungal infections, declined 19% and 20% in the third
quarter and first nine months of 2021, respectively, primarily due to generic competition in Europe, partially offset by higher demand in China. The patent that
provided market exclusivity for 	Noxafil 	in a number of major European markets expired in December 2019. As a result, the Company is experiencing lower
demand for 	Noxafil 	in these markets as a result of generic competition and expects the decline to continue.
- 41 -

-- 41 of 59 --

In December 2020, the Company temporarily suspended sales of 	Zerbaxa, a combination antibacterial and beta-lactamase inhibitor for the treatment of
certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. The Company expects a phased
resupply for 	Zerbaxa 	beginning with the U.S. market in the fourth quarter of 2021.
Immunology
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Simponi 	$ 	203 	$ 	209 	(3) 	% 	(5) 	% 	$ 	619 	$ 	615 	1 	% 	(5) 	%
Sales of 	Simponi 	(golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia
and Turkey), declined 3% in the third quarter of 2021 and increased 1% in the first nine months of 2021. Excluding the effect of foreign exchange, sales
performance in both periods was largely attributable to lower pricing in Company’s marketing territories in Europe, partially offset by higher volumes. Sales of
Simponi 	are being unfavorably affected by biosimilar competition for competing products. The Company expects this competition will continue to unfavorably
affect sales of 	Simponi.
The Company’s marketing rights with respect to 	Simponi 	will revert to Janssen Pharmaceuticals, Inc. in the second half of 2024.
Virology
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Isentress/Isentress HD 	$ 	189 	$ 	205 	(8) 	% 	(7) 	% 	$ 	590 	$ 	646 	(9) 	% 	(9) 	%
Global combined sales of 	Isentress/Isentress HD 	(raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the
treatment of HIV-1 infection, declined 8% and 9% in the third quarter and first nine months of 2021, respectively, primarily due to competitive pressure
particularly in Europe and the U.S. The Company expects competitive pressure for 	Isentress/Isentress HD 	to continue.
Cardiovascular
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Alliance Revenue - Adempas/Verquvo 	$ 	100 	$ 	83 	20 	% 	20 	% 	$ 	248 	$ 	216 	15 	% 	15 	%
Adempas 	59 	55 	7 	% 	8 	% 	188 	167 	13 	% 	7 	%
Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4 to the
condensed consolidated financial statements).
Adempas (riociguat), a cardiovascular drug for the treatment of certain types of pulmonary arterial hypertension, is part of a worldwide collaboration
with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Adempas (see Note 4 to the condensed consolidated financial
statements). Alliance revenue from the collaboration grew 20% and 15% in the third quarter and first nine months of 2021, respectively. Revenue from the
collaboration also includes sales of Adempas in Merck’s marketing territories, which grew 7% and 13% in the third quarter and first nine months of 2021,
respectively, primarily reflecting higher demand.
In January 2021, the FDA approved Verquvo (vericiguat), an sGC stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization
following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection
fraction. Verquvo was also approved in Japan in June 2021 and in the EU in July 2021. The approvals were based on the results of the VICTORIA trial. Verquvo is
part of the same collaboration with Bayer referenced above that includes Adempas.
(1)
(1)
- 42 -

-- 42 of 59 --

Diabetes
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Januvia/Janumet 	$ 	1,339 	$ 	1,327 	1 	% 	— 	% 	$ 	3,895 	$ 	3,948 	(1) 	% 	(4) 	%
Worldwide combined sales of 	Januvia 	(sitagliptin) and 	Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined
1% in the first nine months of 2021 primarily due to continued pricing pressure and lower demand in the U.S., largely offset by higher demand in China and Latin
America. The Company expects U.S. pricing pressure to continue. 	Januvia 	and 	Janumet 	will lose market exclusivity in the U.S. in January 2023. The
supplementary patent certificates that provide market exclusivity for 	Januvia 	and 	Janumet 	in the EU expire in September 2022 and April 2023, respectively. The
Company anticipates sales of 	Januvia 	and 	Janumet 	in these markets will decline substantially after loss of market exclusivity.
Animal Health Segment
Three Months Ended
September 30, % Change
Excluding
Foreign
Exchange
Nine Months Ended
September 30, % Change
Excluding
Foreign
Exchange	($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Livestock 	$ 	864 	$ 	758 	14 	% 	12 	% 	$ 	2,503 	$ 	2,145 	17 	% 	14 	%
Companion Animal 	553 	462 	20 	% 	18 	% 	1,804 	1,390 	30 	% 	26 	%
Sales of livestock products grew 14% and 17% in the third quarter and first nine months of 2021, respectively, primarily due to higher demand for
ruminant products, including animal health intelligence solutions for animal identification, monitoring and traceability, as well as higher demand for poultry and
swine products. Sales of companion animal products grew 20% and 30% in the third quarter and first nine months of 2021, respectively, primarily due to higher
demand for parasiticides, including the 	Bravecto 	(fluralaner) line of products, as well as higher demand for vaccines.
Costs, Expenses and Other
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	% Change 	2021 	2020 	% Change
Cost of sales 	$ 	3,450 	$ 	3,013 	15 	% 	$ 	9,752 	$ 	8,589 	14 	%
Selling, general and administrative 	2,336 	2,060 	13 	% 	6,804 	6,336 	7 	%
Research and development 	2,445 	3,349 	(27)% 	9,177 	7,609 	21 	%
Restructuring costs 	107 	113 	(5)% 	487 	265 	84 	%
Other (income) expense, net 	(450) 	(312) 	44 	% 	(1,007) 	(637) 	58 	%
$ 	7,888 	$ 	8,223 	(4)% 	25,213 	22,162 	14 	%
Cost of Sales
Cost of sales increased 15% and 14% in the third quarter and first nine months of 2021, respectively. Cost of sales includes the amortization of
intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $346 million and $403 million in the third
quarter of 2021 and 2020, respectively, and $1.2 billion and $1.4 billion for the first nine months of 2021 and 2020, respectively. Costs in the first nine months of
2021 also include charges of $225 million related to the discontinuation of COVID-19 development programs. Also included in cost of sales are expenses
associated with restructuring activities which amounted to $48 million and $38 million in the third quarter of 2021 and 2020, respectively, and $113 million and
$131 million for the first nine months of 2021 and 2020, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure
of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in 	Restructuring
costs 	as discussed below.
Gross margin was 73.8% in the third quarter of 2021 compared with 72.4% in the third quarter of 2020. The gross margin increase reflects lower
amortization of intangible assets (noted above), as well as the favorable effect of product mix, partially offset by higher manufacturing costs, including asset write-
offs. Gross margin was 72.3% in the first nine months of 2021 compared with 71.9% in the first nine months of 2020. The gross margin increase reflects lower
amortization of intangible assets and the favorable effect of product mix, partially offset by higher costs associated with COVID-19 development programs,
including charges related to the discontinuation of certain COVID-19 development programs, as well as the unfavorable effects of pricing pressure, higher
manufacturing costs and foreign exchange.
- 43 -

-- 43 of 59 --

Selling, General and Administrative
Selling, general and administrative (SG&A) expenses increased 13% and 7% in the third quarter and first nine months of 2021, respectively, primarily
due to higher administrative costs, including compensation and benefits, higher promotional expenses in support of the Company’s key growth pillars, as well as
the unfavorable effect of foreign exchange. The COVID-19 pandemic contributed to lower spending in the prior year periods.
Research and Development
Research and development (R&D) expenses declined 27% in the third quarter of 2021 primarily due to lower upfront payments related to
collaborations, partially offset by higher oncology and COVID-19 clinical development spending, increased investment in discovery research and early drug
development, as well as higher compensation and benefit costs. R&D expenses increased 21% in the first nine months of 2021 primarily due to higher upfront
payments related to acquisitions and collaborations, as well as higher clinical development spending and increased investment in discovery research and early drug
development. The COVID-19 pandemic contributed to lower spending in the prior year periods.
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division
that focuses on human health-related activities, which were $1.8 billion and $1.6 billion in the third quarter of 2021 and 2020, respectively, and $5.3 billion and
$4.6 billion in the first nine months of 2021 and 2020, respectively. Also included in R&D expenses are Animal Health research costs, licensing costs and costs
incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were
approximately $710 million and $625 million for the third quarter of 2021 and 2020, respectively, and $2.1 billion and $1.9 billion in the first nine months of 2021
and 2020, respectively. Additionally, R&D expenses in the first nine months of 2021 include a $1.7 billion charge for the acquisition of Pandion as noted above.
R&D expenses in the third quarter and first nine months of 2020 include charges of $832 million related to transactions with Seagen Inc. (Seagen) (see Note 3 to
the condensed consolidated financial statements).
Restructuring Costs
In 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing
the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant
rationalization, builds on prior restructuring programs and does not include any actions associated with the spin-off of Organon. As the Company continues to
evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further
actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the
cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.0 billion. The Company expects to record
charges of approximately $700 million in 2021 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will
result in annual net cost savings of approximately $900 million by the end of 2023.
Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $107 million and $113
million for the third quarter of 2021 and 2020, respectively, and were $487 million and $265 million for the first nine months of 2021 and 2020, respectively.
Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount
reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related
costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and
share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in 	Cost of sales, 	Selling, general and administrative 	expenses and
Research and development 	costs. The Company recorded aggregate pretax costs of $168 million and $185 million in the third quarter of 2021 and 2020,
respectively, and $630 million and $500 million, for the first nine months of 2021 and 2020, respectively, related to restructuring program activities (see Note 5 to
the condensed consolidated financial statements).
Other (Income) Expense, Net
Other (income) expense, net, was $450 million of income in the third quarter of 2021 compared with $312 million of income in the third quarter of
2020 primarily due to higher income from investments in equity securities, net, largely related to higher realized and unrealized gains on certain investments,
partially offset by higher pension settlement costs. Other income (expense), net, was $1.0 billion of income in the first nine months of 2021 compared with $637
million of income in the first nine months of 2020 primarily due to higher income from investments in equity securities, net, largely related to higher realized and
unrealized gains on certain investments including the disposition in 2021 of the Company’s ownership
- 44 -

-- 44 of 59 --

interest in Preventice Solutions Inc. (Preventice) as a result of the acquisition of Preventice by Boston Scientific. The favorability in the year-to-date period was
partially offset by higher pension settlement costs.
For details on the components of Other (income) expense, net, see Note 12 to the condensed consolidated financial statements.
Segment Profits
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions) 	2021 	2020 	2021 	2020
Pharmaceutical segment profits 	$ 	8,606 	$ 	7,026 	$ 	22,450 	$ 	19,235
Animal Health segment profits 	505 	459 	1,629 	1,347
Other non-reportable segment profits 	— 	(1) 	— 	1
Other 	(3,845) 	(4,778) 	(14,109) 	(12,175)
Income from continuing operations before taxes 	$ 	5,266 	$ 	2,706 	$ 	9,970 	$ 	8,408
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal
Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal
management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as
described above, R&D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain
responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not
included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-
related costs, including the amortization of intangible assets and amortization purchase accounting adjustments, intangible asset impairment charges, and expense
or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other
expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above
table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales.
Pharmaceutical segment profits increased 22% and 17% in the third quarter and first nine months of 2021, respectively, reflecting higher sales and the
favorable effect of foreign exchange, partially offset by higher administrative and promotional costs. Animal Health segment profits grew 10% and 21% in the
third quarter and first nine months of 2021, respectively, reflecting higher sales, partially offset by higher promotional, selling and administrative costs.
Taxes on Income
The effective income tax rates from continuing operations were 13.2% and 14.0% for the third quarter of 2021 and 2020, respectively, and 14.4% and
15.1% for the first nine months of 2021 and 2020, respectively. The effective tax rates from continuing operations in the third quarter and first nine months of 2021
reflect the beneficial impact of the settlement of a foreign tax matter. The effective income tax rate from continuing operations for the first nine months of 2021
reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207 million related
to the settlement of certain federal income tax matters as discussed below.
In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a
result, the Company was required to make a payment of $190 million (of which $172 million related to Merck continuing operations and $18 million related to
Organon discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this
examination period and therefore the Company recorded a $236 million net tax benefit in the first nine months of 2021 (of which $207 million related to Merck
continuing operations and $29 million related to Organon discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits
and other related liabilities for tax positions relating to the years that were under examination.
Non-GAAP Income and Non-GAAP EPS from Continuing Operations
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes
this information enhances investors’ understanding of the Company’s results as it permits investors to understand how management assesses performance. Non-
GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business
performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs,
income and losses from investments in equity securities, and certain other items.
- 45 -

-- 45 of 59 --

These excluded items are significant components in understanding and assessing financial performance. Non-GAAP income and non-GAAP EPS are important
internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP EPS. Management uses these
measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP EPS are not measures determined
in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures
of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net
income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP).
A reconciliation between GAAP financial measures and non-GAAP financial measures (from continuing operations) is as follows:
Three Months Ended
September 30, Nine Months Ended
September 30,
($ in millions except per share amounts) 	2021 	2020 	2021 	2020
Income from continuing operations before taxes as reported under GAAP 	$ 	5,266 	$ 	2,706 	$ 	9,970 	$ 	8,408
Increase (decrease) for excluded items:
Acquisition and divestiture-related costs 	445 	447 	1,445 	1,600
Restructuring costs 	168 	185 	630 	500
Income from investments in equity securities, net 	(684) 	(346) 	(1,503) 	(944)
Other items:
Charge for the acquisition of Pandion 	— 	— 	1,704 	—
Charges for the discontinuation of COVID-19 development programs 	— 	— 	225 	—
Charges for the formation of collaborations 	— 	1,082 	— 	1,082
Other 	(87) 	(1) 	(26) 	(17)
Non-GAAP income from continuing operations before taxes 	5,108 	4,073 	12,445 	10,629
Taxes on income from continuing operations as reported under GAAP 	695 	380 	1,436 	1,271
Estimated tax (expense) benefit on excluded items 	(30) 	272 	86 	411
Net tax benefit from the settlement of certain federal income tax matters 	— 	— 	207 	—
Adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition 	— 	(67) 	— 	(67)
Non-GAAP taxes on income from continuing operations 	665 	585 	1,729 	1,615
Non-GAAP net income from continuing operations 	4,443 	3,488 	10,716 	9,014
Less: Net income attributable to noncontrolling interests as reported under GAAP 	4 	2 	9 	1
Non-GAAP net income from continuing operations attributable to Merck & Co., Inc. 	$ 	4,439 	$ 	3,486 	$ 	10,707 	$ 	9,013
EPS from continuing operations assuming dilution as reported under GAAP 	$ 	1.80 	$ 	0.92 	$ 	3.36 	$ 	2.81
EPS difference 	(0.05) 	0.45 	0.86 	0.74
Non-GAAP EPS from continuing operations assuming dilution 	$ 	1.75 	$ 	1.37 	$ 	4.22 	$ 	3.55
Includes $832 million related to transactions with Seagen (see Note 3 to the condensed consolidated financial statements).
The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
Acquisition and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures. These
amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration,
transaction, and certain other costs associated with acquisitions and divestitures. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible
assets related to collaborations and licensing arrangements.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 5 to the condensed consolidated financial statements).
These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs
represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be
closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring
costs also include asset abandonment, facility shut-down and other related costs, as well as
(1)
(2)
(1)
(2)
- 46 -

-- 46 of 59 --

employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based
compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or
through ownership interests in investment funds.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis,
considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or
not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2021 is a charge for the acquisition of Pandion, charges related
to the discontinuation of COVID-19 development programs (see Note 3 to the condensed consolidated financial statements) and a net tax benefit related to the
settlement of certain federal income tax matters (see Note 13 to the condensed consolidated financial statements). Excluded from non-GAAP income and non-
GAAP EPS in 2020 are upfront payments related to collaborations, including transactions with Seagen (see Note 3 to the condensed consolidated financial
statements), and an adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition.
Research and Development Update
MK-4482 (EIDD-2801), molnupiravir, is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are
at risk for progressing to severe COVID-19 and/or hospitalization. In October 2021, Merck submitted an EUA application to the FDA for molnupiravir based on
positive results from a planned interim analysis of the Phase 3 MOVe-OUT clinical trial in which molnupiravir significantly reduced the risk of hospitalization or
death in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. The FDA subsequently announced a November 30, 2021 meeting of its
Antimicrobial Drugs Advisory Committee to discuss the available data supporting the use of molnupiravir to treat mild-to-moderate COVID-19 in adults who have
tested positive for COVID-19 and who are at high risk of progression to severe COVID-19, including hospitalization or death. In October 2021, the EMA initiated
a rolling review for molnupiravir. Merck plans to work with the CHMP of the EMA to complete the rolling review process to facilitate initiating the formal review
of the Marketing Authorization Application. Merck is developing molnupiravir in collaboration with Ridgeback Bio. The companies are actively working with
other regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months. Molnupiravir is also being
evaluated for post-exposure prophylaxis in the Phase 3 MOVe-AHEAD trial, which is evaluating the efficacy and safety of molnupiravir in preventing the spread
of COVID-19 within households. As previously announced, data from the MOVe-IN clinical trial indicated that molnupiravir is unlikely to demonstrate a clinical
benefit in hospitalized patients, who generally had a longer duration of symptoms prior to study entry; therefore, the decision was made not to proceed to Phase 3.
MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or
unexplained chronic cough in adults under review by the FDA. The New Drug Application (NDA) for gefapixant is based on results from the COUGH-1 and
COUGH-2 clinical trials. In July 2021, the FDA informed Merck of its decision to extend the goal date for the NDA to provide time for a full review of the
submission. The extended Prescription Drug User Fee Act (PDUFA) date, or target action date, is March 21, 2022. Gefapixant is also under review in the EU and
Japan.
V114, 	Vaxneuvance 	(Pneumococcal 15-valent Conjugate Vaccine), is an investigational 15-valent pneumococcal conjugate vaccine under review by the
EMA for the prevention of invasive disease and pneumonia in adults. In October 2021, the EMA’s CHMP recommended the approval of 	Vaxneuvance 	for active
immunization for the prevention of invasive disease and pneumonia caused by 	Streptococcus pneumoniae 	in individuals 18 years of age and older. The CHMP
recommendation will now be reviewed by the EC for marketing authorization in the EU, and a final decision is expected by the end of 2021. The CHMP opinion
was based on data from seven randomized, double-blind clinical studies evaluating 	Vaxneuvance 	in a variety of adult populations and clinical circumstances. The
Company has several ongoing Phase 3 trials evaluating V114 in pediatric patients. In August 2021, Merck announced positive topline results from the pivotal
Phase 3 PNEU-PED study evaluating the immunogenicity, safety, and tolerability of 	Vaxneuvance 	in infants and has submitted a supplemental licensure
application to the FDA for pediatric use. V114 previously received Breakthrough Therapy designation from the FDA for the prevention of invasive pneumococcal
disease in pediatric patients 6 weeks to 18 years of age.
Keytruda 	is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals
were the result of a broad clinical development program that currently consists of more than 1,600 clinical trials, including nearly 1,200 trials that combine
Keytruda 	with other cancer treatments. These studies encompass more than 30 cancer types including: biliary tract, estrogen receptor positive breast cancer,
cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin
lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-
- 47 -

-- 47 of 59 --

negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
Keytruda 	is under priority review by the FDA for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC
melanoma following complete resection. This submission is based on data from the Phase 3 KEYNOTE-716 trial. In August 2021, Merck announced that the
KEYNOTE-716 trial met its primary endpoint of recurrence-free survival for the adjuvant treatment of patients with surgically resected high-risk stage IIB and IIC
melanoma. These results were presented at the European Society of Medical Oncology (ESMO) Congress in September 2021. The FDA set a PDUFA date of
December 4, 2021. 	Keytruda 	is also under review in the EU for this indication.
Keytruda 	is also under priority review by the FDA for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence
following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions based on data from the Phase 3 KEYNOTE-
564 trial. The FDA set a PDUFA date of December 10, 2021. 	Keytruda 	is also under review in the EU and Japan for this indication.
Additionally, 	Keytruda 	is under review by the FDA for the treatment of patients with advanced endometrial cancer that is MSI-H or dMMR, who have
disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. This submission is based on data from
the KEYNOTE-158 trial. The FDA set a PDUFA date of March 28, 2022.
Keytruda 	in combination with chemotherapy is under review in the EU and Japan for the treatment of patients with high-risk, early-stage TNBC as
neoadjuvant treatment, and then as a single agent as adjuvent treatment after surgery based on the KEYNOTE-522 trial.
Keytruda 	is under review in Japan in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or
metastatic carcinoma of the esophagus or HER2-negative gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 based on the results
from the KEYNOTE-590 trial.
Additionally, 	Keytruda 	is under review in Japan for treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed
after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.
Keytruda 	in combination with platinum-based chemotherapy with or without bevacizumab is also under review in Japan for the first-line treatment of
patients with persistent, recurrent or metastatic cervical cancer based on the KEYNOTE-826 trial.
In October 2021, the CHMP of the EMA adopted a positive opinion recommending approval of the combination of 	Keytruda 	plus Lenvima for the first-
line treatment of adult patients with advanced RCC based on data from the Phase 3 KEYNOTE-581 trial/Study 307. The CHMP also adopted a positive opinion
recommending approval of 	Keytruda 	in combination with Lenvima for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have
disease progression following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation, based
on data from the Phase 3 KEYNOTE-775 trial/Study 309. The CHMP’s recommendations will now be reviewed by the EC for marketing authorization in the EU
and decisions are expected in the fourth quarter of 2021. 	Keytruda 	is also under review for both of these indications in Japan.
Merck and Eisai have stopped LEAP-007, the Phase 3 study evaluating the first-line treatment of Lenvima in combination with 	Keytruda 	in participants
with metastatic squamous or non-squamous NSCLC, whose tumors are PD-L1 positive with no 	EGFR 	or 	ALK 	genomic tumor aberrations. The trial has been
discontinued following the recommendation of the external Data Monitoring Committee (eDMC) which met, as scheduled, to assess safety and futility. The eDMC
determined that the study had met the criteria for declaring futility and the benefit/risk profile of the combination did not support continuing the trial.
Merck and Eisai have closed LEAP-011 for further enrollment. LEAP-011 is a Phase 3 study evaluating Lenvima in combination with 	Keytruda 	for the
first-line treatments of patients with platinum-ineligible urotherial carcinoma. Enrollment was closed following the recommendation of the eDMC, which met, as
scheduled, to assess safety and futility. Data from the study will be presented at an upcoming medical meeting.
- 48 -

-- 48 of 59 --

In April 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) which was being evaluated for the
treatment of hospitalized patients with COVID-19. Merck acquired MK-7110 in December 2020 through its acquisition of OncoImmune, a privately held clinical-
stage biopharmaceutical company. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential EUA application
and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and
regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on
accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the
treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207 million in the first nine months of 2021, which are reflected in 	Cost of
sales 	and relate to fixed-asset and materials write-offs, as well as the recognition of liabilities for purchase commitments.
In September 2021, the FDA approved updated labeling for Steglatro, Steglujan and Segluromet, medicines for adults with type 2 diabetes, to include
the primary efficacy and safety results from the VERTIS CV trial, which assessed the effect of Steglatro compared with placebo on cardiovascular outcomes in
adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The FDA issued a Complete Response Letter (CRL) concerning the
Company’s application for a new indication, based on additional results from the VERTIS CV trial, to reduce the risk of hospitalization for heart failure. The
Company is reviewing the CRL to assess next steps.
The chart below reflects the Company’s research pipeline as of October 27, 2021. Candidates shown in Phase 3 include specific products and the date
such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed
compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given
MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the
same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
- 49 -

-- 49 of 59 --

Phase 2 	Phase 3 (Phase 3 entry date) 	Under Review
Cancer
MK-0482
Non-Small Cell Lung
MK-1026
Hematological Malignancies
MK-1308 (quavonlimab)
Non-Small-Cell Lung
MK-1308A (quavonlimab+pembrolizumab)
Advanced Solid Tumors
Colorectal
Hepatocellular
Melanoma
Small-Cell Lung
MK-2140
Breast
Non-Small-Cell Lung
MK-3475 	Keytruda
Advanced Solid Tumors
MK-4280 (favezelimab)
Hematological Malignancies
Non-Small-Cell Lung
MK-4280A (favezelimab+pembrolizumab)
Renal Cell
Small-Cell Lung
MK-4830
Non-Small-Cell Lung
Small-Cell Lung
MK-5890
Non-Small-Cell Lung
Small-Cell Lung
MK-6440 (ladiratuzumab vedotin)
Breast
Esophageal
Gastric
Head and Neck
Melanoma
Non-Small-Cell Lung
Prostate
Small-Cell Lung
MK-6482 	Welireg
Biliary
Colorectal
Pancreatic
Rare cancers
Von Hippel-Lindau Disease-Associated Tumors (EU)
MK-7119 Tukysa
Advanced Solid Tumors
Biliary Tract
Bladder
Cervical
Colorectal
Endometrial
Gastric
Non-Small-Cell Lung
MK-7339 Lynparza
Advanced Solid Tumors
MK-7684 (vibostolimab)
Melanoma
MK-7684A (vibostolimab+pembrolizumab)
Biliary
Breast
Cervical
Endometrial
Esophageal
Hematological Malignancies
Prostate
MK-7902 Lenvima
Biliary Tract
Glioblastoma
Pancreatic
Prostate
Small-Cell Lung
V937
Breast
Cutaneous Squamous Cell
Head and Neck
Melanoma
Solid Tumors
Cardiovascular
MK-2060
Chikungunya Virus Vaccine
V184
HIV-1 Infection
MK-8591B (islatravir+MK-8507)
MK-8591D (islatravir+lenacapavir)
Nonalcoholic Steatohepatitis (NASH)
MK-3655
MK-6024
Overgrowth Syndrome
MK-7075 (miransertib)
Pneumococcal Vaccine Adult
V116
Pulmonary Arterial Hypertension
MK-5475
Respiratory Syncytial Virus
MK-1654
Schizophrenia
MK-8189
Treatment Resistant Depression
MK-1942
Cancer
MK-1308A (quavonlimab+pembrolizumab)
Renal Cell (April 2021)
MK-3475 	Keytruda
Biliary Tract (September 2019)
Cervical (October 2018) (EU)
Cutaneous Squamous Cell (August 2019) (EU)
Gastric (May 2015) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Ovarian (December 2018)
Prostate (May 2019)
Small-Cell Lung (May 2017)
MK-3475 (pembrolizumab subcutaneous)
Non-Small-Cell Lung (August 2021)
MK-6482 	Welireg
Renal Cell (February 2020)
MK-7119 Tukysa
Breast (October 2019)
MK-7339 Lynparza
Colorectal (August 2020)
Non-Small-Cell Lung (June 2019)
Small-Cell Lung (December 2020)
MK-7684A (vibostolimab+pembrolizumab)
Non-Small-Cell Lung (April 2021)
MK-7902 Lenvima
Colorectal (April 2021)
Esophageal (July 2021)
Gastric (December 2020)
Head and Neck (February 2020)
Melanoma (March 2019)
Non-Small-Cell Lung (March 2019)
HIV-1 Infection
MK-8591A (doravirine+islatravir) (February 2020)
HIV-1 Prevention
MK-8591 (islatravir) (February 2021)
New Molecular Entities/Vaccines
Antiviral COVID-19
MK-4482 (molnupiravir) (U.S.) 	(EU)
Cough
MK-7264 (gefapixant) (U.S.) (EU) (JPN)
Pneumococcal Vaccine Adult
V114 (EU) (JPN)
Certain Supplemental Filings
Cancer
MK-3475 	Keytruda
• Resected Stage IIB and IIC Melanoma
(KEYNOTE-716) (U.S.) (EU)
• Adjuvent Renal Cell Cancer
(KEYNOTE-564) (U.S.) (EU) (JPN)
• MSI-H or dMMR Endometrial Cancer
(KEYNOTE-158) (U.S.)
• High-Risk Early-Stage Triple-Negative Breast Cancer
(KEYNOTE-522) (EU) (JPN)
• Advanced Unresectable Metastatic Esophageal Cancer
(KEYNOTE-590) (JPN)
• Tumor Mutational Burden-High (KEYNOTE-158) (JPN)
• Cervical Cancer (KEYNOTE-826) (JPN)
MK-7902 Lenvima
• First-Line Metastatic Hepatocellular Carcinoma
(KEYNOTE-524) (U.S.)
• Advanced Unresectable Renal Cell Carcinoma
(KEYNOTE-581) (EU) (JPN)
• Advanced Endometrial Cancer
(KEYNOTE-775) (EU) (JPN)
Footnotes:
Being developed in a collaboration.
Being developed in combination with 	Keytruda.
Being developed as monotherapy and/or in combination with 	Keytruda.
Under review for Emergency Use Authorization.
In July 2020, the FDA issued a Complete Response Letter for Merck’s and Eisai’s
applications. Merck and Eisai intend to submit additional data when available to the
FDA.
(2)
(2)
(2)
(1)(3)
(3)
(1)
(1)(3)
(2)
(1)(2)
(1)
(3)
(1)
(1)(3)
(1)(2)
(4)
(1)(2)
(5)
(1)
(2)
(3)
(4)
(5)
- 50 -

-- 50 of 59 --

Liquidity and Capital Resources
($ in millions) 	September 30, 2021 	December 31, 2020
Cash and investments 	$ 	10,451 	$ 	8,835
Working capital 	7,330 	437
Total debt to total liabilities and equity 	28.3 	% 	34.7 	%
Cash provided by operating activities from continuing operations was $8.0 billion in the first nine months of 2021 compared with $4.2 billion in the
first nine months of 2020 reflecting stronger operating performance. Cash provided by operating activities from continuing operations in the first nine months of
2021 includes $400 million of payments related to collaborations compared with $2.1 billion in the first nine months of 2020. Cash provided by operating activities
from continuing operations continues to be the Company’s primary source of funds to finance operating needs, capital expenditures, treasury stock purchases and
dividends paid to shareholders.
Cash used in investing activities of continuing operations was $4.4 billion in the first nine months of 2021 compared with $4.5 billion in the first nine
months of 2020. The lower use of cash in investing activities was driven primarily by lower cash used for acquisitions, largely offset by lower proceeds from sales
of securities and other investments and higher capital expenditures.
Cash used in financing activities of continuing operations was $2.1 billion in the first nine months of 2021 compared with $4.2 billion in the first nine
months of 2020. The lower use of cash in financing activities was primarily driven by the cash distribution received from Organon in connection with the spin-off
(see Note 2 to the condensed consolidated financial statements), lower payments on debt (see below) and lower purchases of treasury stock, partially offset by
lower proceeds from the issuance of debt (see below), a higher net decrease in short-term borrowings and higher dividends paid to shareholders.
Capital expenditures totaled $3.2 billion and $3.0 billion for the first nine months of 2021 and 2020, respectively.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company
factored $2.4 billion and $2.1 billion of accounts receivable at September 30, 2021 and December 31, 2020, respectively, under these factoring arrangements,
which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed
Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related
to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in
the Condensed Consolidated Statement of Cash Flows.
Dividends paid to stockholders were $5.0 billion and $4.7 billion for the first nine months of 2021 and 2020, respectively. In May 2021, the Board of
Directors declared a quarterly dividend of $0.65 per share on the Company’s stock for the third quarter that was paid in July 2021. In July 2021, the Board of
Directors declared a quarterly dividend of $0.65 per share on the Company’s stock for the fourth quarter that was paid in October 2021.
In January 2021, the Company’s $1.15 billion, 3.875% notes matured in accordance with their terms and were repaid. In October 2021, the Company’s
€1.0 billion, 1.125% notes matured in accordance with their terms and were repaid.
In February 2020, the Company’s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were
repaid.
In June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25
billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering
for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming
maturities.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase
authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated
transactions. In May 2021, Merck restarted its share repurchase program, which the Company had temporarily suspended in March 2020. The Company purchased
$822 million (11 million shares) of its common stock during the first nine months of 2021. As of September 30, 2021, the Company’s remaining share repurchase
authorization was $5.1 billion.
- 51 -

-- 51 of 59 --

The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper
borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Estimates
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated
financial statements for the year ended December 31, 2020 included in Merck’s Form 10‑K filed on February 25, 2021. See Note 1 to the condensed consolidated
financial statements for information on the adoption of new accounting standards during 2021. A discussion of accounting estimates considered critical because of
the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates
section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K. There have been no
significant changes in the Company’s critical accounting estimates since December 31, 2020.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative
Disclosures about Market Risk” in the Company’s 2020 Form 10-K filed on February 25, 2021.
Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the
Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial
Officer have concluded that as of September 30, 2021, the Company’s disclosure controls and procedures are effective. For the third quarter of 2021, there were no
changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over
financial reporting.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,”
all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set
forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,”
“forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not
relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product
potential, development programs and include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such
statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors
include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking
statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of
factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In
Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December 31, 2020, filed on February 25, 2021, in the Company’s
Form 10-Q for the quarterly period ended March 31, 2021, filed on May 5, 2021, in the Company’s Form 10-Q for the quarterly period ended June 30, 2021, as
filed on August 9, 2021, and in this Form 10-Q, the Company discusses in more detail various important risk factors that could cause actual results to differ from
expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should
understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all
potential risks or uncertainties.
- 52 -

-- 52 of 59 --

PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 9 included in Part I, Item 1, Financial Statements (unaudited) —
Notes to Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form
10-K for the year ended December 31, 2020. There have been no material changes to the risk factors as previously disclosed in the Company’s Annual Report on
Form 10-K, except as follows:
The global COVID-19 pandemic is having an adverse impact on the Company’s business, operations and financial performance. The Company
is unable to predict the full extent to which the pandemic and related impacts will continue to adversely impact its business, operations, financial
performance, results of operations, and financial condition.
The Company’s business and financial results have been negatively impacted by the outbreak of Coronavirus Disease 2019 (COVID-19). The duration,
spread and severity of the COVID-19 pandemic is uncertain, rapidly changing and difficult to predict. The degree to which COVID-19 impacts the Company’s
results will depend on future developments, beyond the Company’s knowledge or control, including, but not limited to, the duration and spread of the outbreak, its
severity, the actions taken to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.
Merck continues to believe that global health systems and patients have largely adapted to the impacts of the COVID-19 pandemic, and that while
negative impacts will persist, the trend will continue to improve. For the full year of 2021, Merck assumes a net unfavorable impact to sales of less than 3% due to
the COVID-19 pandemic, all of which relates to the Pharmaceutical segment. To the extent these assumptions prove to be incorrect, the Company’s results may
differ materially from the estimates set forth herein.
For the third quarter and first nine months of 2021, the estimated negative impact of the COVID-19 pandemic to Merck’s sales was approximately $350
million and $1.3 billion, respectively, all of which related to the Pharmaceutical segment. Roughly 75% of Merck’s Pharmaceutical segment revenue is comprised
of physician-administered products, which, despite strong underlying demand, have been affected by social distancing measures and fewer well visits.
Operating expenses reflect a minor positive effect in the third quarter and first nine months of 2021 as investments in COVID-19-related research
programs largely offset the favorable impact of lower spending in other areas due to the COVID-19 pandemic.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended September 30, 2021 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period
Total Number
of Shares
Purchased
Average Price
Paid Per
Share
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs
July 1 - July 31 	1,636,842 	$77.33 	$5,522
August 1 - August 31 	2,029,851 	$76.37 	$5,367
September 1 - September 30 	4,104,249 	$73.35 	$5,066
Total 	7,770,942 	$74.97 	$5,066
Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.
(1) 	(1)
(1)
- 53 -

-- 53 of 59 --

Item 6. Exhibits
Number 	Description
3.1 	— 	Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) – Incorporated by reference to Current Report on Form
8-K filed on November 4, 2009 (No. 1-6571)
3.2 	— 	By-Laws of Merck & Co., Inc. (effective July 22, 2015) – Incorporated by reference to Current Report on Form 8-K filed on July 28,
2015 (No. 1-6571)
31.1 	— 	Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer
31.2 	— 	Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer
32.1 	— 	Section 1350 Certification of Chief Executive Officer
32.2 	— 	Section 1350 Certification of Chief Financial Officer
101.INS 	— 	XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded
within the Inline XBRL document.
101.SCH 	— 	XBRL Taxonomy Extension Schema Document.
101.CAL 	— 	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	— 	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	— 	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	— 	XBRL Taxonomy Extension Presentation Linkbase Document.
104 	— 	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
- 54 -

-- 54 of 59 --

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
MERCK & CO., INC.
Date: November 5, 2021 	/s/ Jennifer Zachary
JENNIFER ZACHARY
Executive Vice President, General Counsel and Corporate Secretary
Date: November 5, 2021 	/s/ Rita A. Karachun
RITA A. KARACHUN
Senior Vice President Finance - Global Controller
- 55 -

-- 55 of 59 --

Exhibit 31.1
CERTIFICATION
I, Robert M. Davis, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: November 5, 2021
By: 	/s/ Robert M. Davis
ROBERT M. DAVIS
President and Chief Executive Officer

-- 56 of 59 --

Exhibit 31.2
CERTIFICATION
I, Caroline Litchfield, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: 	November 5, 2021
By: 	/s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

-- 57 of 59 --

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report
on Form 10-Q for the quarter ended September 30, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Date: November 5, 2021 	/s/ Robert M. Davis
Name:
Title: ROBERT M. DAVIS
President and Chief Executive Officer

-- 58 of 59 --

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report
on Form 10-Q for the quarter ended September 30, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Dated: November 5, 2021 	/s/ Caroline Litchfield
Name:
Title: CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

-- 59 of 59 --